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INTRODUCTION 
Cardiovascular disease (CVD) is becoming more preva-
lent worldwide and is one of the leading causes of death 
[1]. To lower CVD mortality, aggressive and comprehen-
sive management of its risk factors, including dyslip-
idemia, hypertension, diabetes mellitus, and smoking, 
are crucial [2]. The incidence of coronary artery disease 
(CAD) is rising in South Korea and although cerebral 
hemorrhage has declined since 2002, cerebral infarction 
is on the rise [3]. This is speculated to be due to the ele-
vated prevalence of dyslipidemia and diabetes mellitus 
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with the growing obesity population, while hyperten-
sion is well-managed and smoking rate has reached a 
plateau [4]. Thus, aggressive diagnosis and treatment of 
dyslipidemia, the most important risk factor for ath-
erosclerosis, are critical for lowering the incidence and 
mortality of CAD and cerebral infarction. 
To promote appropriate treatment of dyslipidemia, 
the Korean Society of Lipid and Atherosclerosis (KSo-
LA) published the first guidelines for the management 
of hyperlipidemia in 1996, the second guideline in 2003, 
the second revision in 2009, and the third guidelines for 
treatment of dyslipidemia with added contents in 2015, 
in collaboration with 18 other relevant academic societ-
ies and organizations [5]. However, new guidelines were 
published in Europe in 2016 and in the United States 
in 2017 based on new study findings, and new drugs, 
such as proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors have been launched [6-8]. Therefore, 
the KSoLA Treatment Guideline Committee developed 
the fourth guidelines for treatment and management of 
dyslipidemia specific to Koreans based on evidence and 
expert opinions on the dynamically changing treatment 
modalities for dyslipidemia. 
The fourth guideline consists of information about 
the epidemiology of dyslipidemia, diagnosis and treat-
ment criteria, lifestyle interventions, drug therapy, and 
dyslipidemia in specific patient groups. Finally, we pres-
ent currently available data and the need to develop and 
validate scales to assess the risk of CVD specific to Ko-
reans and CVD biomarkers appropriate for the Korean 
population. The level of evidence and strength of rec-
ommendations used in the fourth guideline are shown 
in Table 1. The fourth guideline is available in full text 
and an abstract form including tables and figures in Ko-
rean. This paper is an English summary of the full text. 
We hope the fourth guidelines for the treatment of dys-
lipidemia will be useful for health professionals treating 
dyslipidemia. 
EPIDEMIOLOGY OF DYSLIPIDEMIA IN KOREANS 
Cardiovascular disease in Koreans 
CVD is the leading cause of deaths worldwide, with an 
estimated 17 million people dying from CVD every year 
[1,2]. In South Korea, the death rate resulting from dis-
Table 1. Levels of evidence: classes of recommendation
Definition Phrasing
Level of evidence
A Clear evidence for the recommendation 
Clearly proven through multicenter RCTs or meta-analysis with adequate content 
and power with high generalizability of findings 
B Reliable evidence for the recommendation 
Evidence found through well-performed cohort or patient-control group studies 
C Possible evidence for the recommendation 
Not reliable, but relevant evidence found through small RCTs, observational 
studies, or case series 
E Expert opinions 
No supporting evidence, but expert opinions based on clinical experience and 
expertise 
Classes of recommendation
Class I Clear evidence (A) and benefits, and high applicability in practice Recommended
Class IIa Reliable evidence (B) and benefits, and high or moderate applicability in practice Should be considered
Class IIb Unreliable evidence (C or D) and benefits, but high or moderate applicability in 
practice 
May be considered
Class III Unreliable evidence (C or D), may cause harm, and low applicability in practice Not recommended
RCT, randomized controlled trial.
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eases of the circulatory system was 187 men per 100,000 
population and 145 women per 100,000 population in 
1983 and 111 men per 100,000 population and 125 wom-
en per 100,000 in 2016, indicating little change over the 
years. However, the age-adjusted mortality rate, which 
excludes the influence of aging of the population during 
this period, decreased to about one-fifth of the initial 
rate (Fig. 1). Death from CAD has consistently increased 
since 1983, when the cause of death statistics were first 
measured, reaching 31 men per 100,000 and 26 wom-
en per 100,000 in 2016. However, age-adjusted mortal-
ity of CAD reached a peak in the early and mid-2000s 
and began to decline since then (Fig. 2). Deaths from 
cerebrovascular disease declined since 2000s, reaching 
44 men per 100,000 and 47 women per 100,000 in 2016. 
Age-adjusted mortality for cerebrovascular disease has 
declined very quickly (Fig. 3). Among various cerebro-
vascular diseases, there were more deaths from cerebral 
hemorrhage (non-traumatic intracerebral hemorrhage 
and subarachnoid hemorrhage) until 2002, but deaths 
from cerebral infarction (ischemic stroke) have become 
more common since then. This is speculated to be due 
to the marked decline in the incidence and improved 
treatment outcomes of cerebral hemorrhage as a result 
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Figure 1. Trends of cardio-cerebrovascular mortality among Koreans, 1983 to 2016 (source: cause of death statistics). (A) Mor-
tality rate (not age-adjusted). (B) Age-adjusted mortality rate (with reference to 2005 population).
Figure 2. Trends of coronary artery disease mortality among Koreans, 1983 to 2016 (source: cause of death statistics). (A) Mor-
tality rate (not age-adjusted). (B) Age-adjusted mortality rate (with reference to 2005 population).
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of advances in treatment for hypertension [9].
The prevalence and incidence of CVD are not accu-
rately known due to a lack of nationwide statistics. Based 
on a review of various studies, however, the prevalence 
of CVD is rising and the trend of incidence is predicted 
to vary according to the type of disease. Recent studies 
using health insurance claims data have reported the in-
cidence of acute myocardial infarction (MI) to be about 
50 and 10 per 100,000 for men and women, respectively 
[4,5,9]. For cerebrovascular disease, the incidence of cere-
bral infraction and cerebral hemorrhage differs, where 
cerebral hemorrhage is declining quickly while cerebral 
infarction is slowly rising, eventually resulting in the 
number of cases of cerebral infraction outnumbering 
those of cerebral hemorrhage. It is generally believed that 
the incidence of CVD differs across regions and over time 
due to the changing distribution of CVD risk factors [10]. 
The prevalence of hypertension in South Korea is largely 
consistent with the smoking rate reaching a lower pla-
teau; however, the prevalence of diabetes mellitus and 
dyslipidemia is on the rise. Thus, it is predicted that CAD 
would become the most prevalent CVD in Korea [11,12].
CVD risk factors and risk assessment for Koreans 
The risk factors for CVD are well known, and the in-
cidence of CVD varies across regions and time paral-
leling the distribution of these CVD risk factors across 
regions and time [10]. Among CVD risk factors, those 
that have a significant impact on the disease but are able 
to be treated are referred to as major modifiable risk 
factors and include hypertension, diabetes, dyslipid-
emia, and smoking [12]. Other CVD risk factors include 
family history, old age, lack of exercise, obesity, chronic 
inflammation, blood coagulation abnormalities, met-
abolic syndrome, depression, and stress. A Korean co-
hort study that analyzed the population attributable risk 
found that the contribution is the highest for hyperten-
sion, followed by smoking, dyslipidemia, and diabetes 
in men; the contribution by all four risk factors reach-
es 64%. In Korean women, the factor with the highest 
contribution to CVD risk was hypertension, followed by 
dyslipidemia, diabetes, and smoking (Table 1) [13]. Re-
cently, many studies have attempted to assess CVD risk 
based on a comprehensive review of exposure to vari-
ous CVD risk factors [14]. Since the development of the 
Framingham risk score by the Framingham Heart Study 
to compute the 10-year risk of CAD using seven items 
of information (age, sex, total cholesterol, high density 
lipoprotein cholesterol [HDL-C], blood pressure, diabe-
tes, and smoking), various CVD prediction models have 
been developed, and a CVD prediction recommendation 
guideline has been formulated. In South Korea, there 
are studies available that developed a stroke risk model, 
a CAD risk model, and a CVD risk assessment model 
using data from health check-up recipients [13,15-19].
Distribution of lipid concentration in Koreans 
The distribution of serum lipid concentrations varies 
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Figure 3. Trends of cerebrovascular disease mortality among Koreans, 1983 to 2016 (source: cause of death statistics). (A) Mor-
tality rate (not age-adjusted). (B) Age-adjusted mortality rate (with reference to 2005 population).
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according to sex and age and there is a notable differ-
ence among women before and after menopause. Total 
blood cholesterol concentration was reported to slightly 
decrease in the 15- to 19-year-old age group compared to 
that in the 10- to 14-year-old group, but increase again 
after the age of 20 years in both sexes [20]. In the teen 
years, total cholesterol is higher among women. In in-
dividuals in their thirties and forties, total cholesterol is 
higher among men, but women actually have a higher 
total cholesterol concentration after the mid-50s (Fig. 
4A). Distribution of low density lipoprotein cholesterol 
(LDL-C) concentration is similar to that of total choles-
terol (Fig. 4B) [20]. Triglyceride concentration on rapidly 
increases from the age of 10 to 40 years, is maintained 
at a high level between ages 40 to 60, and gradually de-
creases after the age of 60 in men. Conversely, in wom-
en, triglyceride concentration is very low until the ages 
of 30 to 40, begins to increase after the mid-40s, and 
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peaks after the age of 65 (Fig. 4C) [20]. HDL-C concentra-
tion is higher among women than men in across all age 
groups, and the gap is greater in the 20- to 30-year-old 
group (Fig. 4D) [20].
The prevalence of hypercholesterolemia in adults 
aged 30 years or older in South Korea (total cholesterol 
≥ 240 mg/dL or on cholesterol-lowering drugs) has risen 
consistently, from 7% and 8% in men and women, re-
spectively, in 2005, to 19% and 20%, respectively, in 2016 
(Fig. 5A) [21]. The prevalence of dyslipidemia was more 
than double that of hypercholesterolemia at 40.5%. Sex- 
and age-differences indicate that the prevalence of dys-
lipidemia in men is the highest between the ages of 55 
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Figure 6. Trends in hypercholesterolemia management (source: 
National Health and Nutrition Examination Survey).
Table 2. Management of hypercholesterolemia by age, 30 years or older (2016) [21]
Variable
Total Male Female
Number % SD Number % SD Number % SD
Awareness ratea
< 30 yr (standardized) 1,176 58.4 1.9 446 56.0 2.9 730 60.5 2.3
30–49 yr 249 32.0 3.3 142 34.5 4.2 107 27.1 5.6
50–64 yr 513 62.4 3.0 172 66.8 4.4 341 59.1 3.3
≥ 65 yr 414 79.7 1.9 132 76.3 3.9 282 81.3 2.4
Treatment rateb
< 30 yr (standardized) 1,176 49.1 1.8 446 48.8 3.0 730 49.4 2.3
30–49 yr 249 22.5 3.0 142 24.7 3.9 107 18.2 4.7
50–64 yr 513 51.3 2.8 172 60.1 4.6 341 44.7 3.3
≥ 65yr 414 74.3 2.0 132 73.7 3.9 282 74.5 2.7
Control rate (based on patients who have the disease)c
< 30 yr (standardized) 1,176 41.3 1.7 446 42.4 2.8 730 40.5 2.0
30–49 yr 249 18.9 2.8 142 20.2 3.7 107 16.5 4.1
50–64 yr 513 42.7 2.8 172 53.0 4.5 341 34.9 3.0
≥ 65 yr 414 63.3 2.2 132 64.4 4.1 282 62.9 2.8
Control rate (based on individuals undergoing treatment)d
< 30 yr (standardized) 626 82.7 1.7 238 86.1 2.5 388 79.9 2.4
30–49 yr 53 81.1 5.9 34 81.7 7.1
50–64 yr 271 82.2 2.7 109 87.0 3.4 162 77.2 3.9
≥ 65 yr 302 84.0 2.2 95 87.3 3.4 207 82.5 2.8
SD, standard deviation.
aHypercholesterolemia awareness rate (≥ 30 years): percentage of individuals diagnosed with hypercholesterolemia by a physi-
cian from the total number of individuals with hypercholesterolemia.
bHypercholesterolemia treatment rate (≥ 30 years): percentage of individuals currently taking cholesterol-lowering drugs for at 
least 20 days a month from the total number of individuals with hypercholesterolemia.
cHypercholesterolemia control rate (≥ 30 years, based on individuals who have the disease): percentage of individuals with total 
cholesterol of < 200 mg/dL from the total number of individuals with hypercholesterolemia.
dHypercholesterolemia control rate (≥ 30 years, based on individuals undergoing treatment): percentage of individuals with to-
tal cholesterol of < 200 mg/dL from the total number of individuals being treated for hypercholesterolemia.
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to 59 years (49%) and gradually declines thereafter, while 
prevalence in women is low between the ages of 20 to 44 
years, after which it rapidly increases to 50% between the 
ages of 60 to 64 years, eventually exceeding that of male 
counterparts (Fig. 5B) [22]. The prevalence of dyslipid-
emia is higher among individuals with other comorbid-
ities, such as obesity, abdominal obesity, and diabetes 
than among those with no comorbidities [23].
Fortunately, indices for management, such as hy-
percholesterolemia awareness rate, treatment rate, and 
control rates, have been improving. The hypercholes-
terolemia awareness rate (the percentage of individuals 
diagnosed among all those who have hypercholesterol-
emia) increased from 24% in 2005 to 58% in 2016. In the 
same period, the treatment rate (the percentage of pa-
tients taking cholesterol-lowering drugs) increased from 
17% to 49%, the patient control rate (the percentage of 
patients with total cholesterol < 200 mg/dL) increased 
from 11% to 41%, and the treated patients control rate 
(the percentage of treated patients with total cholester-
ol < 200 mg/dL) increased from 62% to 83% (Fig. 6) [21]. 
These management indices have improved in both men 
and women overall, but the awareness rate and treatment 
rates have remained low at about 20% to 30% among 
those below age 50 even until recently (Table 2) [21].
DIAGNOSIS AND TREATMENT CRITERIA FOR 
DYSLIPIDEMIA
Recommendation
Content
Strength of 
recommen-
dation
Level of 
evidence
1 Patients with CVD (CAD, 
peripheral artery disease, 
atherosclerotic ischemic stroke, 
transient ischemic attack) are 
classified as a very high-risk 
group, and the treatment goal 
is to lower LDL-C levels to < 
70 mg/dL or by > 50% from the 
baseline level for secondary 
prevention. 
I A
2 If acute myocardial infarction 
occurs, administer statins 
immediately regardless of the 
baseline LDL-C level. 
I A
  3 Patients with carotid disease 
(significant carotid artery 
stenosis), abdominal aortic 
aneurysm, or diabetes are 
classified as a high-risk group. 
For this group, begin treatment 
when LDL-C concentration 
is ≥ 100 mg/dL for primary 
prevention.
I A
4 Patients with two or more major 
risk factors other than LDL-C 
are classified as a moderate-
risk group. For this group, 
administer statin if LDL-C 
concentration is ≥ 130 mg/dL 
even after weeks or months of 
lifestyle adjustment.
II B
5 Patients with one or fewer major 
risk factors other than LDL-C 
are classified as low-risk group. 
For this group, administer 
statin if LDL-C concentration ≥ 
160 mg/dL even after weeks or 
months of lifestyle adjustment.
II B
6 If LDL-C concentration is ≥ 
190 mg/dL, check whether 
the patient has other causes 
for hyperlipidemia, such as 
biliary obstruction, nephrotic 
syndrome, hypothyroidism, 
pregnancy, use of 
glucocorticoids or cyclosporine 
and make necessary 
adjustments. 
I B
7 If LDL-C concentration is 
≥ 190 mg/dL in absence of 
secondary causes, begin statin 
administration regardless of 
the risk. 
I A
8 If blood triglyceride 
concentration rises to ≥ 500 
mg/dL, check for secondary 
causes of triglyceride elevation, 
such as weight gain, drinking, 
carbohydrate intake, chronic 
kidney disease, diabetes, 
hypothyroidism, pregnancy, 
and use of estrogen, tamoxifen, 
or glucocorticoids and for 
other genetic problems that 
may cause abnormal lipid 
metabolism. 
I A
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9 If triglyceride concentration 
is consistently ≥ 500 mg/dL, 
drug therapy, such as fibrate 
and omega-3 fatty acid therapy, 
may be initiated to prevent 
pancreatitis. 
II A
10 If triglyceride concentration 
is between 200–499 mg/dL 
with high LDL-C level, it is 
recommended to begin statin 
administration to primarily 
lower LDL-C concentration to 
the targeted level.
I A
11 If hypertriglyceridemia persists 
(≥ 200 mg/dL) even after 
lifestyle adjustment and statin 
administration in very high-
risk and high-risk patients, 
drugs that lower triglyceride 
levels, such as fibrate or 
omega-3 fatty acids, may be 
additionally used to prevent 
CVD.
II B
Diagnostic approach and criteria 
Dyslipidemia is generally asymptomatic, so a screening 
test is essential to identify patients requiring treatment. 
For screening of dyslipidemia, all adults aged ≥ 21 years 
and younger individuals with other risk factors, such 
as a family history of premature CVD and severe dys-
lipidemia, should undergo a fasting lipid test every 4 to 
6 years to assess total cholesterol, triglyceride, HDL-C, 
LDL-C (calculated using the Friedewald equation or 
perform a direct assay when triglyceride level is ≤ 400 
mg/dL), and non-HDL-C levels [6,24].
For the measurement of triglyceride and LDL-C lev-
els, individuals must fast for at least 12 hours before 
blood sampling. LDL-C concentration can be general-
ly estimated from fasting total cholesterol, triglyceride, 
and HDL-C. That is, if the individual’s triglyceride con-
centration is ≤ 400 mg/dL, very low density lipoprotein 
cholesterol (VLDL-C) concentration can be estimated by 
dividing the triglyceride value by 5. As total cholesterol 
is the sum of LDL-C, HDL-C, and VLDL-C concentra-
tions, LDL-C concentration can be calculated using the 
Friedewald equation below: 
However, if the individual’s triglyceride concentration 
> 400 mg/dL, the LDL-C value estimated from the above 
equation is less accurate. In such cases, we recommend 
using the LDL-C direct assay [25]. In addition, the cause 
of hypertriglyceridemia should be further investigated. 
Treatment guideline
In this treatment guideline, we maintained the existing 
system of differentiating target LDL-C concentration 
based on the level of CVD risk factors, as previously 
used in the current treatment guideline in Korea, but 
modified and supplemented the specific risk factors and 
treatment standards with reference to study findings 
in Korea and abroad as well as with the 2013 American 
College of Cardiology (ACC)/American Heart Associa-
tion (AHA), 2016 European Society of Cardiology (ESC)/
European Atherosclerosis Society (EAS), and treatment 
guidelines published in other countries [6]. One bene-
fit of the 2013 ACC/AHA treatment guideline is that it 
simplified the criteria for statin administration to “four 
statin benefit groups,” but it has been reported that the 
practical application of the criteria would be difficult 
due to several problems [21]. Therefore, we did not devi-
ate significantly from the third revision of Korean dys-
lipidemia guidelines. 
Very high-risk group 
Patients with CVD (CAD, peripheral artery disease, isch-
emic stroke, transient ischemic attack) are classified as 
the very high-risk group. For this group, the goal should 
be set to lowering LDL-C to < 70 mg/dL or by more 
than 50% of the baseline level for secondary prevention. 
Furthermore, when acute MI occurs, statin should be 
immediately administered regardless of the baseline 
LDL-C concentration (Tables 3 and 4). 
In a foreign randomized trial to test low-dose or high-
dose statin administration on 10,000 patients with stable 
angina with LDL-C < 130 mg/dL, lowering LDL-C level 
close to 70 mg/dL with high-dose statin administration 
reduced CVD risk by about 22% [26]. Furthermore, a me-
ta-analysis of patients who received statin reported that 
preventive effects against CVD were the greatest when 
LDL-C was reduced to a level < 70 mg/dL or by > 50% of 
the baseline level [27].
The 2018 AACE/ACE guidelines recommend that pa-
tients with atherosclerotic CVD and (1) atherosclerotic 
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CVD continuing to progress even after lowering LDL-C 
to < 70 mg/dL, (2) diabetes, (3) stage 3 or 4 chronic kidney 
disease, (4) heterozygous familial hypercholesterolemia 
(heFH), or (5) history of premature atherosclerotic CVD 
(men < 55 years, women < 65 years) should be classified 
into the extreme risk group and that the target for LDL-C 
should be set to < 55 mg/dL [28]. This recommendation 
stems from the Improved Reduction of Outcomes: Vy-
torin Efficacy International Trial (IMPROVE-IT), which 
proved the superiority of combined statin and ezetimibe 
therapy for patients with acute coronary artery syn-
drome, and the Further Cardiovascular Outcomes Re-
search with PCSK9 Inhibition in Subjects with Elevated 
Risk (FOURIER) study and the ODYSSEY OUTCOMES 
trial, which confirmed the effects of PCSK9 inhibitors 
[29-31]. These three studies documented that lowering 
the targeted LDL-C concentration to below the previous 
target is additionally beneficial for prevention of ma-
jor CVD events particularly for the extreme risk group. 
These findings suggest that it may be necessary to lower 
the LDL-C target level for patients with clinical apparent 
atherosclerotic CVD (particularly acute coronary artery 
syndrome). However, additional studies are needed to 
investigate cost-effectiveness and application in Korean 
patients.
Furthermore, a foreign randomized trial on 4,700 pa-
tients who experienced ischemic stroke or transient 
ischemic attack within 6 months found that the LDL-C 
concentration was 73 mg/dL in the statin group and 129 
mg/dL in the placebo group and that the risks of stroke 
and CVD significantly decreased by 16% and 20%, re-
spectively, in the statin group, which suggested that 
Table 3. Treatment according to risk and LDL-C concentration 
Risk
LDL-C, mg/dL
< 70 70–99 100–129 130–159 160–189 ≥ 190
Very high-risk groupa
Coronary artery disease
Atherosclerotic 
ischemic stroke and 
transient ischemic 
attack
Peripheral artery 
disease
Lifestyle 
modification 
and consider 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
High-risk group
Carotid artery diseaseb
Abdominal aneurysm
Diabetesc
Lifestyle 
modification
Lifestyle 
modification 
and consider 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Moderate-risk groupd
Two or more major risk 
factors
Lifestyle 
modification
Lifestyle 
modification
Lifestyle 
modification 
and consider 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Lifestyle 
modification 
and begin 
drug therapy
Low-risk groupd
One or fewer major  
 risk factors
Lifestyle modi-
fication
Lifestyle mod-
ification
Lifestyle  
modification
Lifestyle mod-
ification and 
consider drug 
therapy
Lifestyle mod-
ification and 
begin drug 
therapy
Lifestyle mod-
ification and 
begin drug 
therapy
LDL-C, low density lipoprotein cholesterol.
aIn case of acute myocardial infarction, begin statin therapy immediately regardless of the baseline LDL-C. Statin therapy may 
be considered for very high-risk group other than acute myocardial infarction even if LDL-C is < 70 mg/dL. 
bIn case of significant stenosis of the carotid artery. 
cLevel of risk may be raised depending on the patient if patient has target organ damage or major cardiovascular disease risk 
factor.
dFor moderate-risk and low-risk groups, statin therapy is considered when high LDL-C persists even after weeks or months of 
lifestyle modification.
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lowering LDL-C to close to 70 mg/dL through statin ad-
ministration would also be helpful for patients who had 
an ischemic stroke [32]. However, considering that the 
Korea Medical Insurance Corporation (KMIC) study and 
Japan’s National Integrated Project for Prospective Ob-
servation of Non-communicable Disease and its Trends 
in the Aged (NIPPON DATA80) cohort study reported 
that hypertension, as opposed to hypercholesterolemia, 
was more strongly associated with cerebrovascular dis-
eases and that high-dose statin administration reduced 
the incidence of ischemic stroke but increased that 
of hemorrhagic stroke, additional Korean studies are 
needed to further investigate the statin dose and LDL-C 
targets for preventing ischemic stroke [33]. 
When acute MI occurs, it is recommended to adminis-
ter statins immediately regardless of the baseline LDL-C 
level. In a randomized controlled trial (RCT) on 4,500 
patients who experienced an acute MI, the incidence of 
CVD was lower in the group that received statin immedi-
ately after MI than in the group that did not receive sta-
tin immediately after MI [34]. In a Korean study, though 
a retrospective follow-up using registry, of about 1,000 
patients whose LDL-C concentration was < 70 mg/dL at 
the time of MI, the 1-year incidence of CVD was lower 
in the group that immediately received statin than in 
the group that did not [35]. Thus, in light of Korean and 
foreign study findings, it is recommended to administer 
statin immediately after acute MI regardless of the base-
line LDL-C concentration.
High-risk group
Patients with carotid disease (significant carotid artery 
stenosis), abdominal aortic aneurysm, or diabetes are 
classified as a high-risk group. For this group, treatment 
is started when LDL-C concentration is ≥ 100 mg/dL for 
primary prevention [36,37]. Furthermore, for diabetes 
patients with target organ damage or major CVD risk 
factors, the target could be lowered depending on the 
case (Tables 3 and 4).
In the North American Symptomatic Carotid End-
arterectomy Trial (NASCET) that followed-up 1,415 pa-
tients who underwent carotid endarterectomy due to ca-
rotid artery stenosis, the risk of stroke on the ipsilateral 
side over a period of 8 years was 17.1% higher among pa-
tients with a carotid disease [38]. Similarly, the European 
Carotid Surgery Trial (ECST) study showed that patients 
with symptomatic carotid artery stenosis had a higher 
cardiovascular mortality rate, with a 6-year mortality 
of 27% regardless of the degree of stenosis, and the 10-
year cardiovascular mortality was estimated to be 30% 
Table 4. Target LDL-C and non-HDL-C goals according to risk category 
Risk LDL-C, mg/dL Non-HDL-C, mg/dL
Very high-risk group
Coronary artery disease
Atherosclerotic ischemic stroke and transient ischemic attack
Peripheral artery disease
< 70 < 100
High-risk group
Carotid artery diseasea
Abdominal aneurysm
Diabetesb
< 100 < 130
Moderate-risk group
Two or more major risk factorsc
< 130 < 160
Low-risk group
One or fewer major risk factorsc
< 160 < 190
LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.
aIn case of significant stenosis of the carotid artery. 
bThe target may be lowered depending on the patient if patient has target organ damage or major cardiovascular disease risk 
factor.
cAge (male ≥ 45 years, female ≥ 55 years), family history of premature coronary artery disease, hypertension, smoking, hy-
po-HDL-C.
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[39,40]. In addition, many studies reported that among 
patients with carotid artery stenosis without CVD, low-
ering LDL-C by administering statin reduced major car-
diovascular events and mortality [41]. Korean treatment 
guidelines also classified patients with carotid artery 
stenosis as the high-risk group but did not indicate a 
specific degree of stenosis. 
Moderate-risk group
In line with existing Korean treatment guidelines, pa-
tients with two or more major risk factors other than 
LDL-C are classified into the moderate-risk group. Sta-
tin is administered if LDL-C concentration remains > 
130 mg/dL even after weeks or months of lifestyle ad-
justment (Tables 3-5). The major risk factors listed in 
the Adult Treatment Panel (ATP) III and Korean guide-
lines were used. Among these, smoking, hypertension, 
age, sex, and low HDL-C have also been adopted by 
other treatment guidelines, including the 2013 ACC/
AHA, ESC/EAS, and Japan Atherosclerosis Society (JAS) 
[6,24,42]. However, assessing risk based on these major 
risk factors is known to predict only about half of the ac-
tual cardiovascular risk; thus, individualized treatment 
goals should be set in consideration of other risk fac-
tors, such as obesity, physical activity, diet, levels of tri-
glycerides, high sensitivity C-reactive protein (hs-CRP), 
lipoprotein(a), apolipoprotein, fibrinogen, homocyste-
ine, and apolipoprotein B, as well as the ankle-brachial 
blood pressure index, carotid intimal medial thickening 
(< 50% stenosis but with evidence of clinical progression 
or accompanied by atherosclerotic plaque), and coro-
nary calcium score [6,40].
Low-risk group
Patients with one or fewer major risk factor other than 
LDL-C are classified as the low-risk group. In line with 
previous treatment guidelines, statin is administered if 
LDL-C remains > 160 mg/dL even after weeks or months 
of lifestyle adjustment (Table 3). In the revised guide-
line, LDL-C target was set to < 160 mg/dL, but as other 
non-major risk factors were taken into consideration 
for the moderate-risk group, more aggressive treatment 
goals could be also set for the low-risk group depending 
on the case [40]. If LDL-C concentration is > 190 mg/dL, 
other causes of dyslipidemia, such as biliary obstruc-
tion, nephrotic syndrome, hypothyroidism, pregnancy, 
and use of glucocorticoids or a cyclosporine, should be 
investigated and corrected. If LDL-C concentration is > 
190 mg/dL in absence of secondary causes, statin should 
be started irrespective of the level of risk. 
Treatment guidelines for hypertriglyceridemia 
The risk of acute pancreatitis is known to increase when 
blood triglyceride level exceeds 500 mg/dL, and in such 
cases, it is important to investigate secondary caus-
es that may elevate triglyceride concentration, such as 
weight gain, drinking, carbohydrate intake, chronic kid-
ney failure, diabetes, hypothyroidism, pregnancy, and 
use of estrogen, tamoxifen, and glucocorticoids, as well 
as genetic factors that may cause abnormal lipid metab-
olism [24,43]. If triglyceride concentration remains ≥ 500 
mg/dL even in the absence or correction of secondary 
causes, it is recommended to begin fibrate or omega-3 
fatty acid therapy to prevent pancreatitis. Further, statin 
should be administered if triglyceride level is between 
200 to 499 mg/dL with a high LDL-C level so as to pri-
marily lower the LDL-C concentration to the targeted 
level. If hypertriglyceridemia persists (≥ 200 mg/dL) 
even after lifestyle adjustment and statin administra-
tion in the very high-risk and high-risk groups, drugs 
Table 5. Major risk factors other than low density lipoprotein cholesterola
Age: male ≥ 45 years, female ≥ 55 years
Family history of premature coronary artery disease: coronary artery disease before the age of 55 years for men and 65 years 
 for women among parents and siblings
Hypertension: systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg or taking antihypertensive drugs
Smoking
Low HDL-C (< 40 mg/dL)
BP, blood pressure; HDL-C, high density lipoprotein cholesterol.
aHigh HDL-C (≥ 60 mg/dL) is considered as a protective factor, so one risk factor is deducted.
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that lower triglyceride concentration, such as fibrate and 
omega-3 fatty acid, can additionally be used to prevent 
CVD.
Statin, as opposed to other effective triglyceride-low-
ering drugs, such as fibrates, is recommended as the pri-
mary drug for patients with hypertriglyceridemia based 
on the multiple study findings indicating that statin ad-
ministration is helpful for preventing CVD [44]. Wheth-
er fibrate administration is effective in preventing CVD 
remains controversial. In a meta-analysis of RCTs to in-
vestigate the effects of medications for dyslipidemia on 
mortality, statin significantly decreased cardiovascular 
mortality, while fibrate did not significantly lower mor-
tality compared to placebo [45]. Considering that there 
have been no study findings suggesting that fibrate has 
superior effects to statin on preventing CVD in patients 
with hypertriglyceridemia, it would be appropriate to 
primarily administer statin in order to prevent CVD 
caused by hypertriglyceridemia. 
Moreover, whether administration of fibrate or ome-
ga-3 fatty acid in addition to statin for patients with per-
sistent hypertriglyceridemia even after lifestyle adjust-
ment and statin administration lowers CVD risk is still a 
matter of debate. The Action to Control Cardiovascular 
Risk in Diabetes Action to Control Cardiovascular Risk 
in Diabetes (ACCORD) study reported that additional fi-
brate administration to about 5,500 patients with type 2 
diabetes taking statin did not lower CVD or mortality. 
However, the same study found that pre-administration 
triglyceride concentration was low (162 mg/dL) in all 
patients and an additional analysis showed that among 
patients with pre-treatment triglyceride concentration ≥ 
204 mg/dL with low HDL-C (≥ 34 mg/dL), the incidence 
of CVD differed between the fibrate (12%) and placebo 
(17%) groups [46]. Therefore, adding triglyceride-lower-
ing drugs, such as fibrate and omega-3 fatty acid, to the 
statin regimen is recommended for high-risk patients 
with persistent hypertriglyceridemia (≥ 200 mg/dL) even 
after lifestyle adjustment and statin administration to 
prevent CVD.
Follow-up monitoring 
In line with previous Korean guidelines and foreign 
guidelines, the present revision also recommends lip-
id testing prior to administration and another round of 
testing 4 to 12 weeks after beginning administration to 
assess response and compliance, after which it is recom-
mended to perform lipid tests at 3- to 12-month inter-
vals depending on the patient’s cardiovascular risk and 
degree of lipid reduction after drug administration. The 
revised guideline recommends performing a liver func-
tion test in addition to a lipid test. 
In line with the existing guideline, the present revi-
sion also recommends termination of drug adminis-
tration if patient develops myopathy symptoms and 
creatine kinase (CK) levels increase more than 10-fold. 
In Korea, blood creatinine levels should be measured 
before fibrate administration and after 3 months of ad-
ministration and patients should be followed-up every 6 
months if there are no other abnormal findings.
The 2013 ACC/AHA treatment guidelines could not 
be directly applied in Korea, as it did not reflect indi-
vidual differences in drug responses by uniformly rec-
ommending a moderate-to-high dose of statin for all 
patients without a specific LDL-C target level, did not 
clearly examine the benefits and adverse reactions of 
high-dose statin administration, and may overestimate 
CVD risk in Korea. Additional studies are needed on the 
Korean population to set an appropriate statin dose and 
LDL-C target and specific goals for controlling risk fac-
tors and hypertriglyceridemia, which serve as the crite-
ria for primary prevention.
LIFESTYLE INTERVENTIONS FOR DYSLIPID-
EMIA 
Diet therapy: recommendation
Content
Strength of 
recommen-
dation
Level of 
evidence
1 Consume sufficient energy to 
maintain an appropriate body 
weight
I A 
2 Total fat intake should not exceed 
30% of total energy intake
IIa B 
3 Limit saturated fat intake to < 7% of 
total energy intake
I A 
4 Replace saturated fat with 
unsaturated fat but limit omega-6 
polyunsaturated fat intake to < 10% 
of total energy intake
IIa B 
5 Avoid trans fatty acid intake I A 
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6 For patients with 
hypercholesterolemia, limit daily 
cholesterol intake to 300 mg.
IIa B 
7 Limit total carbohydrate intake to < 
65% of total energy intake and sugar 
intake to 10% to 20% of total energy 
intake
IIa B 
8 Eat fiber-rich foods to consume > 25 
g of dietary fiber
I A 
9 Limit daily alcohol intake to 1 to 2 
shots
I A
10 Eat diets rich in whole grains and 
multigrain, beans, vegetables, and 
fish
Eat whole grain and multigrain as 
the staple
Eat sufficient amounts of vegetables
Eat fish, particularly blue-back fish 2 
to 3 times a week
Eat an adequate amount of fresh 
fruits
IIa B
Energy
Obesity and overweight are related to dyslipidemia. 
Many studies with obese or overweight individuals 
found that total cholesterol, LDL-C, and triglyceride 
concentrations decreased with weight loss [47]. There-
fore, Energy intake should be appropriate to maintain 
healthy weight. According WHO criteria, body mass in-
dex (BMI) of ≥ 30 kg/m2 is classified as obesity. Howev-
er BMI of ≥ 25 kg/m2 proposed as obesity in Korea [48]. 
Obese people can expect to improve blood cholesterol 
and triglyceride levels even by losing about 5% to 10% 
of current weight. In general, a low-calorie diet that is 
about 500 kcal less than one’s usual intake has no partic-
ular harm to health and is reasonable to adhere to. 
Fat
Traditionally, it was recommended to limit fat intake 
to treat dyslipidemia. Several studies have reported that 
limiting fat intake improves LDL-C levels, but in most 
cases, it is difficult to conclude that such improvement 
is an outcome of limiting total fat intake, as an interac-
tion of multiple factors, such as weight loss and reduc-
ing saturated fats and trans fats, are involved. Moreover, 
when fat intake is limited, carbohydrate intake relative-
ly increases, which in turn increases blood triglyceride 
level [49]. However, an excessively high-fat diet may have 
an adverse impact on blood lipid levels by increasing sat-
urated fat and energy intake, so an appropriate amount 
of fat should be consumed. The 2016 ESC/EAS guideline 
recommends individualized rules of percent fat intake 
but to take precaution so as not to exceed 35% of total 
energy consumption, as it may result in elevated satu-
rated fat and energy intake [6]. The average fat intake in 
Korean is about 20%. In Dietary Reference Intake (DRI) 
for Koreans 2015, 15% to 30% fat intake is recommended 
[50,51]. However, considering that percent fat intake varies 
widely across individuals and fat intake has been on the 
rise recently, individuals should take precaution so as not 
to consume fats excessively. Overall, fat intake should be 
limited to within 30% of total energy consumption.
The type of fatty acids has a greater impact on blood 
lipid levels than total fat amount. Replacing saturated 
fats to unsaturated fats could lower blood LDL-C level, 
and substituting trans fats to unsaturated fats contrib-
utes to improving blood triglyceride and HDL-C levels 
[52]. The 2016 ESC/EAS guideline recommends to limit 
saturated fats intake to < 7% of total energy intake and 
to limit trans fat intake to < 1% of total energy intake by 
avoiding processed foods [6]. The 2013 AHA/ACC guide-
line recommends to limit saturated fatty acid intake to 
5% to 6% of total energy intake and to avoid trans fat in-
take [50]. Some rich sources of saturated fats include fats 
of meats, skin of poultry, butter, and palm oil. The ma-
jor sources of trans fats are hydrogenated oils, such as 
margarine and shortening, and trans fats are produced 
during heating oil in high temperature. 
N-3 fatty acids do not have a positive effect on blood 
cholesterol levels but 2 to 4 g of n-3 fatty acids may help 
lower triglyceride level for those with hypertriglycer-
idemia [54]. Although substituting saturated fat with 
polyunsaturated fat is effective in improving blood lipid 
levels, it is recommended to limit n-6 fatty acid intake to 
10% of total energy intake. 
Cholesterol intake has a less of an impact on blood 
LDL-C levels than saturated fats and trans fats and the 
effect varies widely across individuals. Due to insuffi-
cient evidence dietary cholesterol restriction in order to 
prevent serum LDL-C recommendation of dietary cho-
lesterol was excluded from the 2015 Dietary Guideline 
for Americans. The 2013 AHA/ACC guideline does not 
include a recommendation about cholesterol intake [53]. 
The 2016 ESC/EAS guideline recommends cholesterol 
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intake be limited to 300 mg only for individuals with 
high serum cholesterol level [6]. In DRI for Koreans 
2015, it is recommended to reduce dietary cholesterol 
less than 300 mg [51]. In this context, cholesterol intake 
need not be limited uniformly for the prevention of dys-
lipidemia, but excessive intake should be avoided for in-
dividuals with hypercholesterolemia. 
Carbohydrates
Excessive carbohydrate intake, particularly simple sug-
ar intake, elevates blood triglyceride level. In Western 
countries, recommendation on carbohydrate restriction 
is not separately specified, the proportion of carbohy-
drate intake is not high in general population. Instead, 
recommendations suggest simple sugar intake to be 
limited and to eat fiber-rich food sources of carbohy-
drates. Conversely, carbohydrate is a major portion of 
Koreans’ diet, so Koreans should take precautions so 
as not to consume carbohydrates excessively. It is rec-
ommended that the total carbohydrate consumption be 
limited to 65% of daily energy intake, which is the upper 
limit of DRI for Koreans 2015 and simple sugars should 
be limited to 10% to 20% of daily energy intake [51].
Soluble fibers are beneficial in lowering blood cho-
lesterol and triglyceride concentrations, and they are 
found in rich amounts in whole grains, seaweeds, and 
vegetables. The 2016 ESC/EAS guideline recommends 
people to consume 5 to 15 g of soluble fibers (25 to 40 g of 
total dietary fiber) [6,55,56]. It is recommended that peo-
ple eat fiber-rich foods to ingest > 25 g of dietary fiber. 
Alcohol
Excessive alcohol consumption (≥ 10 to 30 g/daily) should 
be avoided, as it increases blood triglyceride levels [57]. 
Hypertriglyceridemia due to alcohol consumption is as-
sociated with suppression of chylomicron degradation 
as a result of reduced lipoprotein lipase (LPL) activity. 
The 2016 ESC/EAS guideline recommends people to 
avoid heavy drinking (< 20 to 30 g for men, < 10 to 20 g 
for women) and to avoid drinking for patients with hy-
pertriglyceridemia [6]. Regardless of the type of alcohol, 
daily drinking should be limited to one to two drinks. 
Dietary pattern
Recent dietary guidelines for CVD tend to emphasize 
the quality of overall diets, rather than focusing on in-
dividual nutrients. These changes are based on the ac-
cumulating evidence that quality of fat intake is more 
important than quantity of fat intake Studies of dietary 
patterns for the Western population such as Dietary 
Approaches to Stop Hypertension (DASH) or Mediter-
ranean dietary patterns reported the effects of dietary 
patterns on blood lipid levels. Based on these results, 
the ACC/AHA guidelines adopt dietary patterns such as 
the DASH, the United States Department of Agriculture 
(USDA) food pattern, and AHA diet for dietary recom-
mendations [53]. The 2016 ESC/EAS guideline also em-
phasizes the importance of healthy food choice [6].
In Korea, few studies have examined the association 
between dyslipidemia and dietary patterns, but diets 
rich in whole grains, such as brown rice and whole 
wheat, with vegetables, legumes, fish, fruits, and dairy 
products may be helpful. Many Korean adults consume 
a typical high-carbohydrate low-fat diet compared to 
Western populations. Therefore, increasing the pro-
portion whole grains instead of refined rice and bal-
anced diet including adequate amounts of fish, beans, 
and fresh vegetables would be beneficial. Furthermore, 
although fresh fruits and milk are recommended, fruit 
concentrates and sweetened milk should be avoided. 
Table 6 shows a list for food choice, and Table 7 shows 
an example of the recommended daily meal plan. The 
dietary guideline to prevent and manage dyslipidemia 
for Koreans is summarized in Fig. 7.
Physical activity: recommendation
Content
Strength of 
recommen-
dation
Level of 
evi-
dence
Physical activities should be 
increased.
I A
Regularly perform at least 30 
minutes of moderate-intensity 
aerobic exercise 4 to 6 times a 
week.
I A
Regularly perform resistance 
exercise at least twice a week. 
IIa B
For individuals with multiple 
risk factors or CVD, a medical 
assessment should be made before 
beginning exercise. 
I A
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Exercise and dyslipidemia
Whether exercise influences blood lipid level is contro-
versial. This is because various results have been report-
ed depending not only on the subjects’ sex, age, race, 
and lipid concentration but also on the type, amount, 
intensity, duration, and frequency of exercise, as well as 
on whether lifestyle and body weight changed with reg-
ular exercise [58]. Furthermore, exercise itself has little 
effect on lipid concentrations. 
There are different types of exercise, including aerobic, 
resistance, and flexibility exercises. Aerobic exercise is 
a type of exercise that increases the body’s oxygen con-
sumption during exercise and improves cardiopulmonary 
endurance. Some examples include speed walking, jog-
ging, swimming, and cycling. Resistance exercise refers to 
exercise in which muscle strength is used to work against 
a weight or force, and this type of exercise increases mus-
cle strength and muscle mass. Flexibility exercise increas-
es the range of motion of major muscles and improves 
postural stability and balance through muscle stretching.
In general, aerobic exercise decreases triglyceride con-
centration while increasing HDL-C, with little changes 
to LDL-C concentration [59,60]. There is no debate in 
that exercise therapy prevents CVD, and CVD preven-
tion is the major goal of dyslipidemia management. 
Therefore, exercise therapy is important for patients 
with dyslipidemia [58,61]. Exercise has been reported to 
lower the risk of CVD as well as CVD mortality and all-
cause mortality by not only improving lipid metabolism 
but also stabilizing blood pressure, improving insulin 
sensitivity, improving inflammation indices, lowering 
body fat, strengthening cardiopulmonary capacity, im-
proving cardiac muscle function, promoting ischemic 
pre-conditioning of cardiac muscles, improving vascu-
lar endothelial functions, improving myocardial flow, 
and having anti-thrombotic effects [62,63].
The effects of resistance exercise on lipids have been 
debated [64,65]. However, resistance exercise could be 
useful because increasing muscle mass and muscle 
strength can increase physical activities and improve ac-
Table 6. The list of foods to be recommended and to be avoided 
Food group
Choose these foods, but be careful  
not to eat excessive
Be careful not to eat too much of these foods and 
eat them too frequently!
Fish/beans/eggs Fish
Bean, tofu
Lean meat
Poultry without skin
Eggs
Ground meat, ribs, internal organs of meats 
Poultry skin, fried chicken
High-fat processed meat products 
Dairies Skim milk, powdered skim milk, low fat milk 
and their products 
Low-fat cheese
Condensed milk and its products
Cheese, cream cheese
Ice cream
Coffee cream
Fats and oils Unsaturated fatty acid: corn oil, olive oil,  
perilla oil, soybean oil, sunflower oil 
Low-fat/non-fat salad dressing 
Butter, pork oil, shortening, bacon oil, beef oil 
Cheese- or whole milk-based salad dressing
Hard margarine
Grains Whole grains Butter and margarine-based bread and cake
High-fat crackers, biscuits, chips, butter 
popcorns 
Pastry, cake, donut, high-fat snack
Soup Soup with fat removed after cooking Oily soup, cream soup
Vegetables/fruits Fresh vegetables, seaweeds, fruits Fried or butter-, cheese-, cream-, or sauce-added 
vegetables/fruits
Sweetened processed products (e.g., canned fruit)
Others Nuts: peanut, walnut Chocolate/sweets
Products with coconut oil or palm oil 
Fried snacks 
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tivities of daily living in the elderly [58].
Exercise prescription
There is no particular exercise prescription for con-
trolling dyslipidemia and the prescriptions are simi-
lar to those for CVD prevention [58,63,66]. In general, at 
least 150 minutes of moderate intensity aerobic exercise 
per week is recommended [63]. Exercise should be per-
formed 4 to 6 days a week and at moderate intensity, 
which is about 55% to 75% of the maximum heart rate 
(= 220 − age) is appropriate. However, CVD patients tak-
Dietary recommendation
Consume energy intake to maintain a healthy weight
Energy
Carbohydrate
Fat
Protein
Dietary fiber: ≥ 25 g
Total carbohydrate:
  ≤ 65% of energy intake
Total sugars:
  < 10–20% of energy intake
Carbohydrate
Limit (≤ 1–2 drinks)
Alcohol
N-6 fatty acids: < 10% of energy inkake
Trans fatty acids: avoid
Cholesterol: < 300 mg/day for 
   hypercholesterolemia
Total fat: ≤ 30% of energy intake
Saturated fatty acids: < 7% of energy intake
Fat
Consume whole grains
(2/3–1 serving/meal)
Consume plenty of 
vegetables
(2.5–3 serving/meal)
Consume fish
lean meat, eggs, or beans
(1–2 serving/meal)
& include fatty fish
2–3 times/week
Consume fresh fruits
(1–2 serving/day)
Consume a 
healthy dietary
pattern
with a focus on
whole grains,
vegetables & fish
Figure 7. Dietary guideline for prevention and treatment dyslipidemia.
Table 7. Example of a daily meal plan
 Food group Recommendation Serving size of typical foods
Grains Whole grain-based diet
2/3 to 1 serving every meal 
Rice (e.g., multigrain rice, brown rice): 210 g (1 bowl) 
Bread (e.g., whole-wheat bread, barley bread): 105 g (3 slices) 
Vegetables Diverse types of vegetables 
2.5 to 3 servings every meal 
Vegetables: 70 g (cooked 1/3 cup) 
Seaweeds: 30 g (cooked 1/5cup) 
Fish meat Fish, lean meat, eggs, tofu 
1 to 2 servings every meal 
Eat blue-backed fish 2 to 3 times a week 
Fish: 60 g (1 piece of medium-size fish) 
Lean meat: 60 g (1.5 ping-pong ball size) 
Eggs: 60 g (1 medium-sized egg) 
Tofu: 80 g (1/5 block) 
Fruits Fresh fruit
1 to 2 servings a day 
1 serving: 100 g (1/2 of medium-sized apple) 
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ing β-blockers or non-dihydropyridine calcium channel 
blockers that markedly lower heart rate must not use the 
target heart rate. For these patients, the intensity should 
be set through an exercise stress test, but if no exercise 
stress test was performed, exercise should be started at a 
“moderate” level and maintained at “somewhat hard” lev-
el. Exercise should consist of 5 to 10 minutes of stretching 
and light walking as warm-up and 30 to 60 minutes of 
main aerobic exercise. Each session could be divided into 
shorter durations depending on one’s abilities. After ex-
ercise, a cool down with 5 to 10 minutes of light walking 
and stretching is needed (Table 8).
Resistance exercise should be performed twice a week, 
but intensity should be set according to age and condi-
tions. In general, it is recommended to perform 8 to 10 
exercise involving major muscle groups for at least 1 set 
of 8 to 12 repetitions each [61,63].
Smoking cessation: recommendation
Content
Strength of 
recommen-
dation
Level of 
evidence
Smoking cessation is strongly 
recommended, as smoking 
increases the risk for dyslipid-
emia and CVD.
I A
Smoking increases plasma free fatty acid levels through 
enhanced lipolysis, which results in insulin resistance. 
Furthermore, smoking impairs reverse cholesterol 
transport [67-69]. According to a meta-analysis, total 
cholesterol, triglyceride, VLDL-C, and LDL-C concen-
trations are 3%, 9.1%, 10.4%, and 1.7% higher, respec-
tively, and HDL-C concentration is 5.7% lower among 
smokers than among non-smokers [70]. After quitting 
smoking, blood HDL-C is significantly increased [71,72]. 
Smoking is a strong risk factor for CVD. The risk as-
sociated with smoking is related to the amount of smok-
ing with no lower limit for deleterious effects [73]. Re-
ducing the amount of smoking is not recommended, as 
it does not increase the possibility of smoking cessation 
and actually makes it more difficult to quit smoking [74]. 
Furthermore, passive smoking also increases the risk 
of CVD [75]. A meta-analysis and RCT confirmed that 
smoking cessation lowers the incidence and mortality 
of CVD [76,77].
Therefore, smoking cessation is strongly recommend-
ed to prevent dyslipidemia and CVD. 
PHARMACOLOGICAL THERAPY FOR DYSLIPID-
EMIA
Guideline summary of pharmacological therapy for 
dyslipidemia
Content
Strength of 
recommen-
dation
Level  
of evi-
dence
1 The primary goal of 
dyslipidemia treatment is 
to lower LDL-C.
I A
2 Non-HDL-C can be 
controlled as a secondary 
goal after achieving 
the targeted LDL-C 
concentration.
II A
3 Appropriate statin 
administration should be 
considered for high-risk 
and very high-risk groups 
in order to meet the LDL-C 
target.
IIa B
Table 8. Summary of exercise therapy for patients with dyslipidemia 
Type and order of exercise Exercise intensity Exercise duration Exercise frequency
Warm-up: light walking after stretching 55% to 75% of  
maximum heart rate
Warm-up: 5–10 min 4–6 days/week
Main exercise: speed walking, power walking, 
cycle ergometer, stepper, cyclone, light hiking
Main exercise: 30–60 min
Cool-down: stretching after light walking Cool-down: 5–10 min
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4 Statin should be considered 
to use for low-risk or 
moderate-risk groups 
when LDL-C level is not 
reduced to the target even 
after weeks and months of 
lifestyle modification.
IIa B
5 Ezetimibe or bile acid 
sequestrants should be 
considered for patients 
with statin intolerance.
IIa B
6 Combination with 
ezetimibe should be 
considered if LDL-C target 
is not achieved even after 
using maximum tolerable 
dose of statin.
IIa B
7 PCSK9 inhibitors may be 
considered to concurrent 
use for the very high-risk 
group if LDL-C target is 
not achieved even after 
using maximum tolerable 
dose of statin alone or with 
ezetimibe.
IIb A
8 Bile acid sequestrants may 
be considered if LDL-C 
target is not achieved even 
after administering statin.
IIb C
9 Combination of statin 
and nicotinic acid is not 
recommended to achieve 
the LDL-C target.
III A
10 If the targeted level is not 
achieved even after using 
statin alone or with other 
agents in the very high-
risk group, reducing 
LDL-C by 50% of the 
baseline concentration is 
recommended.
I A
11 Administer statin 
immediately for patients 
with acute myocardial 
infarction regardless 
of the baseline LDL-C 
concentration.
I A
12 For individuals with a 
triglyceride concentration 
of 500 mg/dL or higher, 
immediate drug therapy 
and lifestyle modification 
are important to prevent 
acute pancreatitis.
I A
13 For individuals with a 
triglyceride concentration 
of 200–499 mg/dL, the 
primary treatment goal is 
to lower the LDL-C to the 
targeted level based on the 
calculated cardiovascular 
risk.
I A
14 For individuals with a 
triglyceride concentration 
of 200–499 mg/dL, 
pharmacological therapy 
should be considered to lower 
triglyceride concentration 
after achieving the targeted 
LDL-C level if triglyceride 
concentration is > 200 mg/dL 
with cardiovascular risk 
factors, or if non-HDL-C 
concentration is above the 
target.
IIa B
15 If indicated, fibrates 
should be used to control 
triglyceride concentration.
I B
16 If indicated, omega-3 fatty 
acids should be considered 
to control triglyceride 
concentration.
IIa B
17 Combination drug therapy 
may be considered if 
targeted triglyceride level is 
not met after monotherapy. 
IIb C
18 The primary goal for low 
HDL cholesterolemia treat-
ment is to control LDL-C to 
below the target.
I A
Selection of drugs 
Pharmacological therapy in addition to therapeutic life-
style modification, such as diet therapy, exercise, and 
smoking cessation, is important for the management of 
dyslipidemia. To determine whether to start drug ther-
apy, a comprehensive consideration should be given to 
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both the CVD risk and LDL-C level for each patient. The 
CVD risk is classified as low risk, moderate risk, high 
risk, and very high risk. Pharmacological therapy can be 
initiated according to established history of CAD, pe-
ripheral artery disease, and ischemic stroke and patients 
with atherosclerotic artery disease (aortic aneurysm, 
transient ischemic attack, carotid artery disease with 
significant stenosis) or diabetes as well as to the number 
of CAD risk factors (smoking, hypertension, low HDL 
cholesterolemia, family history of premature CAD, age). 
Statin is the first line drug for hypercholesterolemia 
and the dosage is recommended to be adjusted to reach 
the target LDL-C level. The primary treatment goal is 
to lower the LDL-C to the target level or below and the 
secondary goal is to lower non-HDL-C concentration to 
target or below. Prior to drug therapy, it is important 
to investigate and correct secondary causes that may in-
crease LDL-C or triglyceride levels (Table 9). Table 10 
describes selection of drugs according to dyslipidemia 
treatment standard.
Hypercholesterolemia
The major independent risk factor associated with im-
proved prognosis in patients with dyslipidemia and 
CVD is the reduction of LDL-C. Statin has been proved 
to lower CVD morbidity and mortality in both prima-
ry and secondary prevention studies, and according to 
a meta-analysis, CVD mortality, cardiovascular events, 
and stroke decreases by 20%, 23%, and 17%, respectively, 
with every 39 mg/dL reduction of LDL-C [27]. Statin is 
the primary pharmacological agent for hypercholester-
olemia, and the dose should be adjusted based on the 
patient’s CVD risk to meet the targeted LDL-C level (I, 
A) [24,78,79].
Very high-risk group are the patients with athero-
sclerotic CVD (CAD, peripheral artery disease, ischemic 
stroke, transient ischemic attack) are classified as the 
very high-risk group. For this group, the goal of treat-
ment is to reduce LDL-C concentration to < 70 mg/dL or 
by more than 50% of the baseline for secondary preven-
tion. Statin should be immediately administered regard-
less of baseline LDL-C concentration for patients with 
acute MI as well as patients who underwent revasculariza-
tion therapy due to atherosclerotic ischemic heart disease. 
For the very high-risk group, use of PCSK9 inhibitors was 
proven to have cardiovascular protective effects, so PCSK9 
inhibitors may be additionally used if the target LDL-C 
concentration is not achieved even after using maximum 
tolerable dose of statin and ezetimibe (IIb, A) [30,80].
High-risk group includes the patients with significant 
carotid artery disease, abdominal aneurysm, and diabe-
tes. Statin treatment should be started if LDL-C is ≥ 100 
mg/dL, and could be selectively considered even for pa-
tients with an LDL-C level of < 100 mg/dL. For patients 
with diabetes with target organ damage or major cardio-
vascular risk factors, the degree of risk could be elevated 
depending on the patient. 
Moderate-risk group includes the patients with two or 
Table 9. Potential causes of secondary hypercholesterolemia or hypertriglyceridemia 
LDL-C elevation Triglyceride elevation
Diet Saturated fat intake
Trans fat intake
Excessive energy intake
Drinking
Excessive energy intake
High carbohydrate diet
Drugs Diuretics
Glucocorticoids 
Amiodarone
Cyclosporin
Oral estrogen, glucocorticoid, bile acid sequestrant, proteolytic 
enzyme inhibitor, retinoic acid, anabolic steroid, sirolimus, 
raloxifene, tamoxifen, β-blocker, thiazide diuretic
Disease Obstructive liver disease
Nephrotic syndrome
Anorexia nervosa
Chronic kidney disease
Nephrotic syndrome
Sepsis
Metabolic disorder Obesity
Pregnancy
Hypothyroidism
Obesity
Pregnancy
Uncontrolled diabetes
LDL-C, low density lipoprotein cholesterol.
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more CV risk factors. For these patients, statin therapy 
should be started when LDL-C is ≥ 130 mg/dL but could 
be started even for those with LDL-C level 100 to 129 
mg/dL when patients have multiple CV risk factors. 
Low-risk group includes the patients with one or few-
er risk factors, stain therapy may be used if the patient’s 
LDL-C is ≥ 160 mg/dL. Drug therapy is used for the low-
risk or moderate-risk group if LDL-C concentration 
level persists to be above the treatment cut-off despite 
weeks or months of therapeutic lifestyle modification 
(IIa, B). Pharmacological treatment strategy for hyper-
cholesterolemia is as follows (Fig. 8).
Hypertriglyceridemia
When triglyceride concentration is high, it is recom-
mended to first determine whether there are other fac-
tors increasing triglycerides and then to establish the 
treatment plan by evaluating the cardiovascular risks 
(Table 9). For individuals with a triglyceride concentra-
tion of 500 mg/dL or higher, immediate drug therapy (I, 
A) and lifestyle modification are important to prevent 
acute pancreatitis. Life style modification in these pa-
tients need to change to a low-fat diet (reduce fat intake 
to 10% to 15% of total energy intake) and complete absti-
nence from alcohol. In addition, pharmacological ther-
apy should be started, particularly using fibrate (I, B) or 
Table 10. Drug selection according to dyslipidemia treatment standard (primary goal: LDL-C; secondary goal: non-HDL-C)
Dyslipidemia 
 classification 
Order Type of drug Method of administration
Strength of 
recommendation
Level of 
evidence
Hypercholesterolemia Basic drugs Statin Adjust dose according to 
CVD risk to meet target 
LDL-C (when meeting  
target is difficult for  
high-risk and very high-
risk groups, adjust dose to 
lower LDL-C by > 50% of 
the baseline) 
I A
Other drugs Bile acid sequestrant, 
 ezetimibe
IIa B
Combination 
therapy
 
Statin + ezetimibe IIa B
Statin + bile acid  
sequestrant
IIb C
Statin (± ezetimibe) + 
PCSK9 inhibitor
Statin (± ezetimibe) for very 
high-risk group when tar-
get LDL-C is not met even 
with statin monotherapy or 
statin/ezetimibe therapy
IIb A
Hypercholesterolemia 
+ hypertriglyceri-
demia
Monotherapy Statin I A
Combination 
therapy
Statin + fibrate IIa A
Statin + gemfibrozil III B
Statin + omega-3 fatty 
acid 
IIa C
Hypertriglyceridemia Basic drugs Fibrate I B
Omega-3 fatty acid IIa B
When drug therapy is 
considered for hypo- 
HDL cholesterolemia 
Basic drugs Statin, fibrate IIb B
LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; CVD, cardiovascular disease; 
PCSK9, proprotein convertase subtilisin/kexin type 9.
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omega-3 fatty acids (IIa, B), which lower triglyceride lev-
els [81-83]. For patients with diabetes, strictly regulating 
blood glucose level using insulin is helpful. 
When the triglyceride level is between 200 to 499 mg/dL, 
the primary treatment goal is to lower the LDL-C to be-
low the target on the basis of the calculated cardiovas-
cular risk (I, A) and the secondary goal is to lower non-
HDL-C to below the target (IIa, A). Therapeutic lifestyle 
modification and statin therapy should be considered (I, 
A). After achieving the target LDL-C goal through ther-
apeutic lifestyle modification and statin therapy, when 
the triglyceride concentration is still > 200 mg/dL or 
non-HDL-C, triglyceride lowering drug therapy may be 
considered (IIa, B). Fibrate (I, B) or omega-3 fatty acids 
(IIa, B) should be used to control triglyceride levels [82,83] 
especially in high-risk and very high-risk groups. If the 
target triglyceride goal is not met with monotherapy, 
combination therapy may be considered (IIa, C) [84].
Low HDL cholesterolemia 
Low HDL cholesterolemia is defined as HDL-C levels 
< 40 mg/dL. It is often observed in patients with type 
2 diabetes, mixed dyslipidemia, chronic kidney dis-
ease, chronic liver disease, and autoimmune disease. 
Low HDL cholesterolemia is often found with hyper-
triglyceridemia. Low HDL cholesterolemia should be 
considered when assessing the overall CAD risk. In the 
Korean National Health and Nutritional Examination 
Survey from 1998 to 2010, hypertriglyceridemia and 
low HDL cholesterolemia are more common than hy-
percholesterolemia [85]. The primary treatment goal for 
low HDL cholesterolemia is to lower the LDL-C to the 
target level based on the patient’s CV (I, A). To increase 
HDL-C while lowering the LDL-C to the target, thera-
peutic lifestyle modification, such as smoking cessation, 
weight loss, and exercise, should be concurrently per-
formed. In patients with low HDL cholesterolemia in 
the very high-risk or high-risk group, the use of agents 
that elevate HDL-C, such as fibrate or nicotinic acid, 
may be considered after controlling LDL-C, but the ad-
ditional cardiovascular protective effects of these agents 
when combined with statin have not been confirmed in 
prospective randomized primary and secondary preven-
tion studies. In particular, nicotinic acid products are 
Evidence-guided approach algorithm of dyslipidemia treatment
Very high risk group < 70 mg/dL
High risk group < 100 mg/dL
Moderate risk group < 130 mg/dL
Yes
Yes
No
No
Very high risk group
• Coronary artery disease
• Atherosclerotic ischemic stroke 
  and transient ischemic attack
• Peripheral artery disease
High risk group
• Carotid artery disease
• Abdominal aortic aneurysm
• Diabetes
Moderate risk group
Assessment of cardiovascular risk
Reached LDL-C target level?
Assessment of adverse effect
• Major risk factors ≥ 2
Statin
Maintain current medication
Maximal tolerated dose of statin
Ezetimibe PCSK9 inhibitor
Figure 8. Drug therapy strategy for hypercholesterolemia. LDL-C, low density lipoprotein cholesterol.
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not currently available in South Korea and treatment to 
elevate HDL-C is no longer recommended (III, A).
Characteristics of lipid-lowering drug 
Statin: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase 
inhibitor
Statin is currently recommended as the first-line phar-
macologic agent among other therapeutic agents, as it 
has relatively few adverse effects and clearly is beneficial 
for reducing CVD by lowering LDL-C [86]. 
 
Mechanism of action
All statins decrease cholesterol synthesis by competitively 
inhibiting the cholesterol precursor, 3-hydroxy-3-meth-
yl-glutaryl coenzyme A (HMG-CoA) reductase [87]. To 
maintain cellular cholesterol homeostasis, LDL recep-
tors are elevated while cholesteryl ester formation is 
decreased. As a result, blood LDL-C is further removed 
and VLDL production in the liver is diminished, conse-
quently lowering LDL. Statins not only block cholesterol 
synthesis but also inhibit the synthesis of lipid interme-
diates, which have important biological effects. Lipid in-
termediates, such as geranylgeranyl pyrophosphate and 
farnesyl pyrophosphate prenylate proteins, enable them 
to be attached to the cellular membrane and promote 
the biological activity of these molecules. One of the 
mechanisms through which statin increase HDL-C is by 
inhibiting the phosphorylation of peroxisome prolifer-
ator-activated receptor α, which regulates geranylgera-
nylation of Rho A and apo A1 transcription. Altering the 
prenylation of a protein appears to partially mediate the 
statin effects other than their LDL-C-lowering effect.
Types of statin
Seven types of stains, namely lovastatin, pravastatin, 
simvastatin, fluvastatin, atorvastatin, rosuvastatin, and 
pitavastatin, are currently used (Table 11).
Lipid-lowering effects
Statins vary in absorption, blood protein binding, elim-
ination, and solubility and the LDL-C lowering effects 
also vary according to dose (Table 11) [85,88-91]. In gen-
eral, increasing statin dose twofold decreases blood 
LDL-C by 6%. Furthermore, statin inhibits VLDL-C 
secretion in the liver, thus it lowers triglyceride levels 
by 22% to 45% in patients with hypertriglyceridemia. 
HDL-C is slightly (5% to 10%) elevated. Multiple studies 
on Koreans have reported the effects of each type of sta-
tin on lipid indices and some studies have shown that 
the same dose of statin leads to a greater reduction of 
LDL-C among Koreans than among foreigners (Figs. 9 
and 10) [92-113].
Cardiovascular disease prevention research and indications 
1) Secondary prevention of CVD
     Patients with a history of CVD (angina, unstable angi-
na, MI, stroke, transient ischemic attack) are known to 
be more vulnerable to relapse of cardiovascular event 
or mortality [102-104]. For these patients, it is recom-
mended to use statins because these drugs prevent the 
recurrence of cardiovascular events (I, A) [24,36,114]. 
These patients are classified as a very high-risk group, 
and the goal is to reduce LDL-C to < 70 mg/dL or by 
> 50% of the baseline for secondary prevention. If 
MI occurs, immediately administer statin regardless 
of the baseline LDL-C concentration (I, A). Although 
there are not many large studies on Asians, preventive 
effects were greater in CVD patients younger than 75 
years old for whom LDL-C was reduced by more than 
30% to 50% using statin than in the group of patients 
whose LDL-C was reduced by a lesser degree using a 
different dose of statin. Therefore, it is recommended 
that moderate dose/moderate intensity or high dose/
high intensity statin be used such that the baseline 
LDL-C concentration can be reduced by more than 
30% to 50% (IIa, A) [24,27,115].
       For CVD patients age > 75 years or older, statin 
therapy should be used after confirming potential in-
teractions with the patient’s comorbidity or between 
drugs used (IIa, B) [24,116].
2)  Primary preventive effects of CVD in the general pop-
ulation  
     Adults with a blood LDL-C concentration of 190 mg/dL 
or higher are likely to develop a CVD in their lifetime, 
so statin should be used if the blood LDL-C remains 
> 190 mg/dL even after appropriate lifestyle modifica-
tion (I, A) [24,86,117,118].
       For adults with blood LDL-C of 160 to 190 mg/dL, 
statin should be used if blood LDL-C remains > 160 
mg/dL even after 4 to 8 weeks of appropriate lifestyle 
modification (IIa, B) [24,27].
       For adults with blood LDL-C of 130 to 160 mg/dL, ap-
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propriate lifestyle modification should be made, and 
statin therapy should be determined to start in con-
sideration of the risk for CVD (IIb, C) [24,27,119,120].
3)  Primary preventive effects of CVD in patients with di-
abetes
     Patients with diabetes, carotid artery disease or aor-
tic aneurysm are considered as high risk group. For 
these patients, statin treatment should be started 
for primary prevention when LDL-C is > 100 mg/dL 
(I, A) [24,117].
4)  Effects of statin in patients with heart failure and pa-
tients undergoing hemodialysis
     Statin does not have any preventive effects in patients 
with heart failure or in hemodialysis patients, so new-
ly adding statin therapy is not recommended for pa-
tients beginning hemodialysis (III, B) [24].
Usage-dosage
Lovastatin: 20 to 80 mg/day, taken with dinner
Pravastatin: 10 to 40 mg/ day, evening administration is 
more effective
Simvastatin: 20 to 40 mg/ day, evening administration is 
more effective
Fluvastatin: 20 to 80 mg/day, evening administration is 
more effective
Atorvastatin: 10 to 80 mg/day, time of administration is 
not significantly relevant
Rosuvastatin: 5 to 20 mg/day, time of administration is 
not significantly relevant
Pitavastatin: 1 to 4 mg/day, time of administration is not 
significantly relevant
Adverse reactions
The most common adverse reactions are indigestion, 
heartburn, and abdominal pain, which occur in 4% and 
hepatotoxicity and muscle toxicity are rare but may be 
fatal [114]. For older adults aged ≥ 75 years, patients tak-
ing multiple drugs, particularly when taking drugs with 
the same metabolic pathway with statin, or in patients 
with comorbidities requiring multidrug therapy, such 
as heart transplantation/acquired immune deficiency 
syndrome, it is helpful to begin with a low dose and 
Table 11. Lipid-controlling efficacy and pharmacological features of currently used statins
Lovastatin Pravastatin Simvasattin Fluvastatin Atorvastatin Rosuvastatin Pitavastatin
Daily dose, mg 20–40 10–40a 20–40 20–80 10–80 5–20b 1–4
LDL-C  
 reduction, %
24–28 20 20 40 1
30–36 40 40 20 80 10 2
39–45 80 40 20 5–10 4
46–52 40–80 20
Metabolism CYP3A4 sulfonation CYP3A4 CYP2C9 CYP3A4 CYP2C9 Glucuronidation
(partial
 CYP2C9)
Protin
 binding, %
> 95 43–67 95–98 98 98 88 > 99
Half-life, hr 2–4 2–3 1–3 0.5–3 13–30 19 12
Hydrophilicity – + – – – + –
Elimination Hepatobiliary Hepatobiliary Hepatobiliary Hepatobiliary Hepatobiliary Hepatobiliary Hepatobiliary
Renal
 elimination
 fraction, %
10 20 13 < 6 < 2 28 15
LDL-C, low density lipoprotein cholesterol; CYP, cytochrome P450.
a40–80 mg in Caucasian countries.
b5–40 mg in Caucasian countries.
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gradually increase the dose (IIa, C).
1)  Hepatotoxicity: There is no need to stop drug ad-
ministration when transaminase is slightly elevat-
ed. If transaminase is increased by more than three 
times the normal range, stop administration, and 
once normal levels are restored, restarting statin with 
a low dose or use another agent may be considered 
(IIb, C). If symptoms suggesting liver injury, such as 
fatigue, reduced appetite, abdominal pain, dark urine, 
and jaundice, manifest during statin therapy, liver 
function tests, including aspartate transaminase/ala-
nine transaminase (AST/ALT), should be performed 
promptly (IIa, C) [24].
2)  Muscle toxicity: The most common adverse reaction 
to statin is muscle pain [114]. About 10% of patients 
taking statin develop muscle pain and weakness and 
stop taking statin, but in many cases, it is uncertain 
whether the muscle symptoms are indeed caused by 
statin [121]. The incidence of muscle injury is reported 
to be 0.01% higher in the statin group than that in 
the control group. It is reported that muscle injury, 
defined as elevated muscle enzymes, rhabdomyolysis, 
hemoglobinuria, and acute kidney failure, occur in a 
small minority of patients. The risk for statin-induced 
muscle damage increases with multiple comorbid-
ities or when statin is combined with cyclosporine, 
fibrate, macrolide antibiotics, and some antifungal 
agents [122]. Gemfibrozil especially increases the risk 
of muscle damage when combined with statin, but 
fenofibrate is known to have low risk. Regular mea-
surement of muscle enzyme levels is not recommend-
ed for asymptomatic patients, as it has shown no ben-
efits (III, A) [24]. However, for patients with muscle 
pain, stiffness, muscle knots, weakness, and general 
fatigue, it is recommended to check for muscle injury 
by measuring muscle enzyme levels (IIa, C) [24].
3)  Diabetes: A recent study reported that statin increas-
es new onset diabetes [120]. Most new-onset diabetes 
occurred in individuals who had glucose intolerance 
prior to taking statin and there is a possibility that it 
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Figure 9. Comparison of low density lipoprotein cholesterol (LDL-C) reduction effects of statins between foreigners and 
Koreans [75-96]. Modified from Cholesterol Treatment Trialists’ Collaboration et al. [27].
Figure 10. Korean data on the lipid-controlling efficacy of 
currently used statins [75-94]. LDL-C, low density lipopro-
tein cholesterol.
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may occur more frequently in patients who had tak-
en a high-dose of statin. Thus, checking fasting blood 
glucose is helpful prior to beginning statin therapy (I, 
B) [24]. Even for patients who developed diabetes after 
beginning statin therapy, it is better to continue tak-
ing statin and make necessary lifestyle modification, 
such as exercise, weight reduction, and smoking ces-
sation, than to stop statin therapy altogether in order 
to prevent CVD (I, B) [24]. 
4)  Cognitive impairment: There has been some report 
that cognitive impairment was observed among pa-
tients taking statin. Nonetheless, to date, it is more 
beneficial to check for adverse reactions of combined 
neuropsychiatric medications than to conclude that 
cognitive impairment is an outcome of statin admin-
istration (IIb, C) [24].
Contraindications
Active or chronic liver disease is an absolute contrain-
dication. Statin administration should be stopped im-
mediately once pregnancy is confirmed or in lactating 
woman. Combination with cyclosporin, macrolide anti-
biotics, antifungal agents, and cytochrome P-450 inhib-
itors is a relative contraindication and must be deter-
mined with caution. 
Follow-up observation before and after statin therapy 
1)  Pre-test: Prior to statin therapy, blood transaminase 
concentration (AST/ALT) should be measured (I, B) 
[24]. If ALT concentration is 3 times higher than the 
normal range prior to therapy, statin therapy should 
be initiated only after assessing and treating liver dis-
ease and confirming that liver functions have been 
improved [24]. Muscle enzyme CK should be mea-
sured as well, and if the concentration is three times 
higher than the normal range, identify the cause first 
and decide on whether to begin statin therapy [24].
2)  Follow-up test after statin therapy: Assess cholesterol, 
triglyceride, and HDL levels about 4 to 12 weeks after 
statin therapy (I, B). If LDL-C is < 40 mg/dL in two 
consecutive measurements, consider lowering the 
dose of statin. Evaluation of liver function should be 
considered at 4 to 12 weeks after administration and 
every 3 to 12 months thereafter check statin effects and 
hepatotoxicity. Furthermore, the physician may pre-
scribe a follow-up-test to ensure patient safety even in 
the absence of symptoms [24].
3)  Effects of cessation statin therapy: Blood LDL-C level 
rises again about 2 to 3 months later and reverts back 
to the pre-treatment levels [116]. In addition, the CV 
protective effects of statin disappear from 1 to 2 days 
after stopping administration, so it is crucial to con-
tinue taking the drug. Particularly, multiple studies 
have reported that pausing statin therapy in the acute 
phase for patients with CVD, such as acute coronary 
artery syndrome or cerebral infarction, leads to poor 
outcomes. 
Summary 
Statin: HMG-CoA reductase inhibitor
Usage/dosage Lovastatin: 20–80 mg/day, taken with 
dinner
Pravastatin: 10–40 mg/day, evening 
administration is more effective
Simvastatin: 20–40 mg/day, evening 
administration is more effective
Fluvastatin: 20–80 mg/day, evening 
administration is more effective
Atorvastatin: 10–80 mg/day, time of 
administration is not significantly 
relevant
Rosuvastatin: 5–20 mg/day, time of 
administration is not significantly 
relevant 
Pitavastatin: 1–4 mg/day, time of 
administration is not significantly 
relevant 
Follow-up test Lipid profile, liver function test, muscle 
enzymes (when there is unexplainable 
muscle pain or muscle weakening)
Adverse reaction Indigestion, heartburn, abdominal pain, 
hepatotoxicity, muscle toxicity, diabetes 
Contraindica-
tion
Active or chronic liver disease, 
pregnancy, and breastfeeding are 
absolute contraindications. Combining 
with cyclosporin, macrolide antibiotics, 
antifungal agents, or cytochrome P-450 
inhibitors is a relative contraindication 
and requires caution. 
Ezetimibe
Indications and action mechanism
Ezetimibe is commonly combined with statin therapy, 
as it lowers LDL-C by inhibiting cholesterol reabsorp-
tion in the small intestine (IIa, B).
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Usage-dosage
Take 10 mg of ezetimibe once a day. There is no relevant 
time of administration.
Follow-up test
Blood lipid profile may be tested every 3 to 6 months. 
Adverse reactions
The most common adverse reactions to ezetimibe 
monotherapy are abdominal pain, diarrhea, flatulence, 
and fatigue and other uncommon adverse reactions 
include indigestion, gastroesophageal reflux, reduced 
appetite, arthralgia, muscle spasm, and chest pain. In 
blood tests, elevation of transaminase, gamma-glutamyl 
transferase (GT), and CK have been reported. 
Contraindications
Ezetimibe is prohibited for individuals who show hy-
persensitivity to this agent. It is also prohibited for 
pregnant and lactating women, as its safety has not been 
established. It is also prohibited for patients with acute 
liver disease or moderate to severe chronic liver dys-
function.
Summary 
Ezetimibe
Usage/dosage 10 mg once daily 
Follow-up test Lipid profile tests every 3–6 months 
Adverse reactions Abdominal pain, diarrhea, flatulence, 
fatigue, indigestion, gastroesophageal 
ref lux, reduced appetite, arthralgia, 
muscle spasm, and chest pain 
Elevated transaminase, gamma-GT, 
and CK
Contraindications Drug hypersensitivity (III, C)
Pregnancy and breastfeeding (III, C)
Acute liver disease or moderate to se-
vere chronic liver dysfunction (III, C)
Fibrate
Indications
Fibrate are used as monotherapy (I,B) or combination 
therapy with statin for hypertriglyceridemia (IIa,A).
Usage-dosage
Bezafibrate: 400 to 600 mg/day, 1 to 3 times a day, after 
meals
Fenofibrate: 160 to 200 mg/day, once a day, immediately 
after meals
Gemfibrozil: 600 to 1,200 mg/day, twice a day, 30 min-
utes before meals
Follow-up tests before and after treatment
Lipid profile, liver function test, kidney function test, 
general blood test, muscle enzymes (when there is unex-
plainable muscle pain or weakness)
Adverse reaction
The most common adverse reaction is indigestion, and 
cholesterol gallstones may occur more frequently. My-
opathy may occur, but the incidence is not high. The 
risk for adverse reactions is elevated when kidney func-
tions (estimated glomerular filtration rate [eGFR]) are 
reduced, as blood drug concentration is increased. In 
particular, combination therapy with gemfibrozil and 
statin increases the risk for myopathy. Fenofibrate is the 
preferred agent for combination therapy with statin, as 
it does not relatively increase the risk for myopathy. It 
binds to albumin, which increases warfarin concentra-
tion and, therefore, bleeding tendency, and it may also 
increase the effects of hypoglycemic agents [123].
Contraindications
Severe liver disease, gallbladder disease, and hypersen-
sitivity to fibrate are absolute contraindications, and use 
of the drug requires precaution for individuals with re-
duced kidney functions [123].
Summary 
Fibrate
Usage/ 
dosage
Bezafibrate: 400–600 mg/day, 1–3 times a 
day, after meals 
Fenofibrate: 160–200 mg/day, once a day, 
immediately after meals 
Gemfibrozil: 600–1,200 mg/day, twice a day, 
30 minutes before meals (avoid combination 
therapy with statin)
Follow-up 
test
Lipid profile, liver function test, general 
blood test, CK (when there is unexplainable 
muscle pain or muscle weakness)
Adverse 
reaction
Indigestion, cholesterol gallstones, 
myopathy 
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Contraindi-
cations
Severe liver disease, gallbladder disease, and 
hypersensitivity to fibrate are absolute con-
traindications, and use of the drug requires 
precaution for individuals with reduced 
kidney function
Monoclonal antibody type PCSK9 inhibitors
Indications
For patients with familial hypercholesterolemia and the 
very high-risk group whose LDL-C levels do not reached 
to target LDL-C level despite statin monotherapy with 
maximum tolerable dose or statin and ezetimibe com-
bination therapy, PCSK9 inhibitors may be combined 
with statin with or without ezetimibe (IIb, A).
Usage-dosage
Alirocumab: 75 or 150 mg via disposable pen or syringe 
At first, subcutaneous injection of 75 mg in 2-week in-
tervals or 300 mg in 4-week intervals. If not reached to 
target LDL-C level, dosage could be increased to 150 mg 
in 2-week intervals. 
Evolocumab: 140 mg/mL via disposable syringe or 
automatic injector, or 420 mg/3.5 mL via disposable on-
body infuser with a prefilled cartridge is injected subcu-
taneous in the abdomen, thigh, or upper arm (140 mg in 
2-week interval or 420 mg in 1-month interval).
Inject 420 mg over 9 minutes using a disposable in-
fuser or inject 140 mg three times consecutively within 
30 minutes. 
Follow-up test
Lipid profile, and liver function test every 3 to 6 months.
Adverse reactions
There may be adverse reactions in the injection site after 
subcutaneous injection of monoclonal antibody, but the 
reactions are generally mild, and other reactions include 
nasopharyngitis. PCSK 9 inhibitors are not known to in-
crease hepatotoxicity, and compared to ezetimibe, there 
are is no elevation in muscle pain or CK levels. There 
are no known interactions with other drugs and adverse 
reactions from prolonged administration. 
Contraindications
Hypersensitivity to alirocumab or evolocumab is an ab-
solute contraindication.
Summary 
PCSK9 inhibitor
Usage/dosage Alirocumab: subcutaneous injection 
of 75 mg or 150 mg 
Evolocumab: subcutaneous injection 
of 140 mg/mL in 2-week interval or 
420 mg in 1-month interval 
Follow-up test Lipid profile 
Adverse reaction Adverse reactions in the injection site
Contraindications Hypersensitivity to alirocumab or 
evolocumab
Omega-3 fatty acids
Indications
Omega-3 fatty acids may be used alone for hypertri-
glyceridemia (IIa, B) or combined with statin for mixed 
hyperlipidemia (IIa, C).
Usage-dosage
Dosage that showed lipid-reduction effects was 2 to 4 g a 
day. This dose should be taken at once or at two split times.
Follow-up test
Lipid profile and liver function tests every 3 to 6 months.
Adverse reaction
There have been some reports of the occurrence of 
hemorrhagic stroke, elevated blood glucose, and elevat-
ed immunosuppression [124-132]. There have also been 
reports of nausea, vomiting, burps, fish-smelling burps, 
or fishy taste in mouth, as well as elevated liver indices, 
headache or itching, and arthralgia. 
Contraindications
There are no contraindications other than hypersen-
sitivity to the drug. The U.S. Food and Drug Adminis-
tration classifies this drug as class C; thus, for pregnant 
women, the drug should be used only when there are 
clear benefits (II, C). Omega-3 fatty acids extracted from 
fish with incomplete purification or excessive intake 
pose a risk for heavy metal exposure, so it is not recom-
mended for pregnant women. It is also not known if this 
drug is secreted in breast milk.
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Summary 
Omega-3 fatty acids
Usage/dosage 2–4 g/day
Follow-up test Lipid profile, liver function test every 
3–6 months
Adverse reaction Hemorrhagic stroke, elevated blood 
glucose, immunosuppression, nau-
sea, vomiting, burp, fish-smelling 
burp, fishy taste in mouth, elevated 
liver indices, headache, itching, 
arthralgia 
Contraindications Hypersensitivity to drug
Nicotinic acid (niacin)
To date, studies have not found significant improve-
ments of clinical outcomes after nicotinic acid and sta-
tin combination therapy, and there were actually more 
adverse reactions [133] Furthermore, there is no ap-
proved product available in South Korea, and niacin and 
statin combination therapy is no longer recommended 
to increase HDL-C (III A).
Combination therapy 
Adding another pharmacologic agent to statin can be 
considered if LDL-C remains high even after adequate 
statin administration and lifestyle modification or pa-
tient has mixed dyslipidemia.
Statin and ezetimibe combination therapy 
Combination of statin and ezetimibe additionally lowers 
LDL-C by 15% to 20% compared to statin monotherapy. 
Ezetimibe (10 mg) and simvastatin (40 mg) combina-
tion therapy significantly reduced major cardiovascular 
events compared to simvastatin (40 mg) monotherapy in 
the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) 
study that assessed simvastatin/ezetimibe therapy in pa-
tients with asymptomatic aortic stenosis, in the Study of 
Heart And Renal Protection (SHARP) on patients with 
chronic kidney disease, and in the IMPROVE-IT on pa-
tients with acute coronary syndrome [24,33,134-136]. As 
clinical trials proved, further lowering LDL-C by adding 
ezetimibe to statin therapy has benefits for improving 
clinical outcomes, so ezetimibe should be added if the 
target LDL-C goal is not met even with maximum toler-
able dose of statin (IIa, B). 
Statin and PCSK9 inhibitor combination therapy 
PCSK9 inhibitors may be considered for very high-risk 
group if the target LDL-C is not met even with maxi-
mum tolerable dose of statin with or without ezetimibe 
or if the patient has statin intolerance. Two types of 
PCSK9 inhibitors, currently available evolocumab and 
alirocumab, lower LDL-C by 50% to 70% regardless of 
statin/ezetimibe therapy for hyperlipidemia [30,137,138]. 
Furthermore, FOURIER study proved that the evolo-
cumab group had a 59% reduction of LDL-C with 15% 
less risk of combined primary outcome, including car-
diovascular mortality, MI, cerebral infarction, hospi-
talization due to unstable angina, and coronary artery 
intervention [30]. Therefore, PCSK9 inhibitors may be 
combined with statin therapy for the very high-risk 
group if LDL-C remains high even after using maxi-
mum tolerable dose of statin (IIb, A).
Statin and fibrate combination therapy 
In the Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) and ACCORD studies that studied of 
statin and fenofibrate therapy in patients with diabetes, 
statin and fibrate combination therapy did not signifi-
cantly lower cardiovascular risk, the primary endpoint 
of the study. However, in a retrospective subgroup 
analysis, the total CVD incidence was 27% lower in the 
dyslipidemia group, who had high triglyceride and low 
HDL-C [46,139,140]. Fibrate, when combined with sta-
tin, were found to be effective in lowering CVD risk in 
some high-risk patients with high triglyceride and low 
HDL-C levels; thus, additional studies are needed to 
prove the clinical efficacy. However, there may be an el-
evation of muscle-related symptoms and diseases as a 
result of fibrate and statin combination therapy, so cli-
nicians should choose agents appropriately and be well 
aware of the indications. 
Stain and bile acid sequestrant combination therapy 
Combination of statin and bile acid sequestrants may be 
considered for achieving the target LDL-C goal. Adding 
bile acid sequestrants to statin therapy may additionally 
lower LDL-C by 10% to 20%. However, there has been 
no clinical trial assessing whether statin/bile acid se-
questrant therapy decreases CVD, while a study using 
coronary artery angiography reported that it lowers ath-
erosclerosis [141].
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Statin and omega-3 fatty acid combination therapy 
These two agents are generally used when aiming to 
lower both LDL-C and triglyceride levels (IIa, C). In 
some early studies, combining low-dose statin with 
eicosapentaenoic acid decreased major cardiovascular 
events compared to statin monotherapy, but multiple 
subsequent studies could not observe significant reduc-
tion of mortality with use of alpha-omega, supplemen-
tation with folate, vitamin B6 and B12 and/or omega-3 
fatty acids, and other studies also did not find signifi-
cant improvements of outcome [83,142].
Statin and niacin combination therapy 
The “Niacin in patients with low HDL cholesterol levels 
receiving intensive statin therapy,” the Atherothrombo-
sis Intervention in Metabolic Syndrome with low HDL/
HIGH Triglycerides (AIM-HIGH) trial reported [133] 
that statin and niacin combination therapy sufficiently 
controlled LDL-C in patients with CVD, but the study 
was prematurely terminated, as there were no signifi-
cant improvements of outcomes in patients with ath-
erogenic dyslipidemia after adding niacin (1.5 to 2 g/day) 
to statin therapy. However, this study also reported that 
it may lower CVD risk in patients with high triglyceride 
but low HDL-C levels. Unfortunately, niacin was associ-
ated with some adverse reactions such as elevated blood 
glucose, blushing, infection, and skin disease, and con-
sequently, it became unavailable in some countries. Fur-
thermore, the “Effects of extended-release niacin with 
laropiprant in high-risk patients,” HPS2-THRIVE study 
reported that adding niacin and facial flushing inhibi-
tor laropiprant to statin therapy could not reduce major 
cardiovascular events and actually led to an increase of 
adverse reactions, such as myopathy, liver dysfunction, 
and increased risk of diabetes [143]. Therefore, statin and 
niacin combination therapy is not recommended (III, A).
DYSLIPIDEMIA IN SPECIAL GROUPS
Dyslipidemia in stroke patients 
Dyslipidemia’s contribution to stroke varies across sub-
types, and the association between dyslipidemia and 
ischemic stroke caused by atherosclerosis is the most 
well known. Dyslipidemia is an important risk factor 
for atherosclerotic ischemic stroke, and multiple clin-
ical trials have shown that aggressive statin therapy can 
lower the incidence of stroke. Conversely, some cohort 
studies have also reported an association between low 
blood cholesterol levels and incidence and mortality of 
hemorrhagic stroke. Therefore, different approaches 
should be taken to treat dyslipidemia in stroke patients 
depending on the type of stroke involved. 
Primary prevention of stroke and dyslipidemia 
Elevated total blood cholesterol and LDL-C are risk factors 
for ischemic stroke and statin therapy is helpful for pri-
mary prevention of ischemic stroke [27,144]. In summary, 
(1)  Statin therapy is recommended for primary preven-
tion of ischemic stroke for patients with a vascular 
disease or those at a high risk of CVD. The target 
LDL-C goal is set according to the general recom-
mendations. 
(2)  For patients with a vascular disease, statin/ezetimibe 
combination therapy may be used for primary pre-
vention of ischemic stroke. 
Secondary prevention of stroke and dyslipidemia 
Statin therapy for secondary prevention of stroke is the 
most effective for atherosclerotic ischemic stroke, and 
its preventive effects are yet unclear for other subtypes of 
stroke [32,145]. High-dose statin therapy has been associ-
ated with increased risk of bleeding in ischemic stroke 
patients with hemorrhagic stroke [32,146]. Considering 
the large number of hemorrhagic stroke patients in 
Korea, high-dose statin therapy should be used careful-
ly. Although research data on the goal of dyslipidemia 
treatment for secondary prevention in stroke patients is 
yet thin, aggressive LDL-C correction is important for 
atherosclerotic ischemic stroke.
In summary, 
(1)  Dyslipidemia must be corrected for ischemic stroke 
patients and for secondary prevention of ischemic 
stroke, lifestyle adjustment, dietary therapy, and 
pharmacologic therapy, particularly statin therapy 
are recommended.
(2)  High-dose statin therapy is recommended for sec-
ondary prevention of stroke for patients with isch-
emic stroke, atherosclerotic ischemic stroke, or 
transient ischemic attack with CVD. The treatment 
goal is to lower LDL-C to < 70 mg/dL or by more 
than 50% of the baseline level. 
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Dyslipidemia in patients with chronic kidney disease
Early phase of chronic kidney disease is characterized by 
elevated levels of triglyceride, reduced HDL-C, and in-
creased LDL, particularly small dense LDL particles. As 
renal function declines, the rate of LDL-C breakdown is 
further slowed and, consequently, total cholesterol and 
LDL-C levels are elevated.
Unlike patients with normal kidney function, the pri-
mary or secondary prevention effects of statin on CVD 
are yet unclear for patients with chronic kidney disease. 
The 2013 The Kidney Disease: Improving Global Out-
comes (KDIGO) guidelines recommended to remove 
LDL-C as a criterion for assessing appropriateness of 
treatment target in the management of dyslipidemia for 
patients with chronic kidney disease and instead pro-
posed the use of future cardiovascular risk (rates per 
1,000 person years) [147]. 
Usage and dosage
The same pharmacologic agent/dose used for healthy 
counterparts is permitted for patients with chronic 
kidney disease with an eGFR of ≥ 60 mL/min/1.73 m2 
(excluding patients who had kidney transplantation). 
There are no clear data on the safety of high-dose statin 
in patients with chronic kidney disease with an eGFR 
of < 60 mL/min/1.73 m2, and there may be potential ad-
verse reactions. Hence, the documented dose in large-
scale studies is recommended for these patients (Table 
12) [135,148-150]. 
Approach to dyslipidemia in patients with chronic kidney disease 
There is no direct evidence that performing blood lipid 
test at the time of diagnosis with chronic kidney disease 
is helpful for the patient’s outcomes. However, blood 
lipid testing is recommended, as it is relatively cheap 
and is helpful for detecting and distinguishing second-
ary dyslipidemia, such as that caused by hypothyroid-
ism, excessive drinking, nephrotic syndrome, diabetes, 
liver disease, and use of other corticosteroid. Uniform 
and regular follow-up tests for LDL-C are not recom-
mended after the diagnosis of chronic kidney disease. 
However, individual follow-up tests may be needed de-
pending on the patient, such as for assessing patient 
adherence, considering change of dialysis method, di-
agnosing other secondary dyslipidemia, or assessing 10-
year cardiovascular risk in patients under the age of 50 
to begin statin therapy. 
Cholesterol-lowering drug therapy in adult patients with 
chronic kidney disease 
Regarding cholesterol-lowering therapy for patients 
with chronic kidney disease, the 2011 guidelines by ESC/
EAS stresses that chronic kidney disease is considered a 
CAD risk equivalent and lowering LDL-C is the primary 
treatment goal for these patients [151]. The 2013 KDIGO 
guidelines suggest classifying individuals with a 10% or 
higher 10-year risk for coronary death or non-fatal MI 
as the statin therapy group [147]. Among patients with 
chronic kidney disease, those aged 50 years or older 
Table 12. Recommended statin dosage for adult patients with chronic kidney disease (mg/day) (KDIGO)a
Statin eGFR G1–G2
eGFR G3a–G5, including patients on dialysis or 
 with a kidney transplant
Lovastatin GPb ND
Pravastatin GP 40
Simvastatin GP 40
Simvastatin/ezetimibe GP 20/10
Atorvastatin GP 20
Fluvastatin GP 80
Rosuvastatin GP 10
Pitavastatin GP 2
KDIGO, Kidney Disease Improving Global Outcomes; eGFR, estimated glomerular filtration; GP, general population; ND, not 
done or not studied.
aKDIGO (2013).
bAny dose approved for general population.
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are recommended to undergo statin/ezetimibe or sta-
tin monotherapy regardless of their eGFR. For patients 
under the age of 50 years, statin or statin/ezetimibe is 
recommended if the patient has a history of CAD, dia-
betes, or ischemic stroke or if the 10-year risk for CAD 
mortality or non-fatal MI exceeds 10%.
For patients with chronic kidney disease requiring 
maintenance dialysis, newly adding statin therapy is not 
recommended, as statin was not found to have signifi-
cant effects in three large-scale prospective randomized 
controlled studies [135,149,150]. Although it is not clear 
whether individuals on statin therapy prior to dialysis 
should stop statin therapy, it is necessary to analyze the 
risk/effects for continuing statin in consideration that 
statin is less effective on these patients compared to 
non-dialysis patients. 
Among patients with chronic kidney disease who 
had a kidney transplantation, the incidence of CAD is 
very high compared to that of the normal population, 
at about 21.5 events/1,000 patient-year [148]. In the same 
study, fluvastatin reduced, though statistically insignifi-
cant, the incidence of CAD by 17% in those patients. For 
the treatment of lipid abnormality, statin is the recom-
mended first-line treatment, but it should be started 
at a low dose and be increased gradually. Considering 
pharmacologic interactions, fluvastatin and pravastatin 
are recommended for transplant patients taking cyclo-
sporine [6].
Triglyceride-lowering drug therapy for adult patients with 
chronic kidney disease 
Therapeutic lifestyle modification should be considered 
first. Using fibric acid derivatives, which had been rec-
ommended in previous guidelines for the prevention 
of pancreatitis, is no longer recommended, as the sup-
porting evidence is very weak. However, fibric acid de-
rivatives may be considered for those with a fasting tri-
glyceride of ≥ 1,000 mg/dL, and if used, the dose should 
be appropriately adjusted depending on the patient’s 
kidney functions. In such cases, patients are considered 
at a high risk for adverse reactions, so combination ther-
apy with statin is not recommended. A large meta-anal-
ysis on the general population reported that fibrate 
therapy decreased major cardiovascular events and cor-
onary events by 10% and 13%, respectively [45]. However, 
the effects are relatively weak compared to that of statin, 
and it elevates serum creatinine levels; thus, fibrate is 
not recommended for the purpose of lowering cardio-
vascular risks for those with chronic kidney disease [152]. 
In addition to pharmacological therapy, non-pharma-
cological therapy, such as dietary therapy, weight loss, 
increasing physical activity, lowering alcohol consump-
tion, and blood glucose control, should be performed. 
Adverse reactions and contraindications
Statin therapy in patients with stage 3 or higher chron-
ic kidney disease may increase the risk of adverse reac-
tions such as drug overdose and increased blood drug 
concentration, so choosing pharmacologic agents with 
low renal excretion is desirable (Table 11) [153]. Further-
more, using drugs that are not metabolized by CYP-3A4 
enzymes would lower adverse reactions caused by drug 
interactions. 
In general, fibric acids are not recommended for pa-
tients with chronic kidney disease, but they may be con-
sidered in special cases. In such cases, the dosage should 
be adjusted based on patient’s renal functions, and it 
should be noted that fibric acids may increase serum 
creatinine levels and that combining with statin may in-
crease the risk of rhabdomyolysis [154,155].
Dyslipidemia in patients with diabetes 
Content
Strength of 
recommen-
dation
Level of
evidence
Patients with diabetes are 
recommended to take blood 
lipid test at the time of diag-
nosis and every year there-
after.
I E
In addition to the routine 
lipid testing (total cho-
lesterol, HDL-C, LDL-C, 
triglyceride), non-HDL-C 
or apoB may be measured to 
assess diabetic dyslipidemia.
IIa A
In diabetic patients without 
CVD, the recommended 
target for LDL-C is < 100 
mg/dL.
I A
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In diabetic patients with 
CVD risk factors or target 
organ damage such as albu-
minuria and chronic kidney 
disease, an LDL-C target of 
<70 mg/dL should be con-
sidered.
I B
Patients with diabetes and 
dyslipidemia must engage 
in aggressive lifestyle modi-
fications. 
I A
Strict glycemic control is 
helpful to control hypertri-
glyceridemia. 
I C
Statin is the first line treat-
ment for patients with 
diabetes and dyslipidemia.
I A
If statin therapy is not suf-
ficient to achieve the target 
LDL-C goal in patients with 
diabetes and CVD, adding 
ezetimibe should be consid-
ered. 
IIa B
If statin therapy is not suf-
ficient to achieve the target 
LDL-C goal in patients with 
diabetes and CVD, adding 
PCSK9 inhibitors may be 
considered. 
IIb B
The risk of CVD is substantially increased with met-
abolic syndrome or diabetes, and CVD is one of the 
leading causes of death among patients with diabetes 
[156]. Because CVD mortality is about two to four times 
higher among patients with diabetes than among those 
without diabetes, dyslipidemia in these patients should 
be treated aggressively [157]. 
Typical diabetic dyslipidemia is characterized by hy 
pertriglyceridemia and decreased HDL-C. Furthermore, 
it is associated with an increased risk of atherosclero-
sis even without a high LDL-C, as small and dense LDL 
particles increase. Therefore, patients with diabetes are 
recommended to measure a lipid profile at the time of 
diagnosis and every year thereafter. In addition to the 
routine lipid tests (total cholesterol, HDL-C, LDL-C, 
triglyceride), non-HDL-C or apoB may be measured to 
assess diabetic dyslipidemia [158].
The present guidelines for the management of dys-
lipidemia classifies patients with CVD as the very high-
risk group regardless of diabetes and recommends 
aggressive regulation of LDL-C to < 70 mg/dL for this 
group. For patients with diabetes without CVD, the goal 
of LDL-C < 100 mg/dL is recommended, but for those 
patients with CVD risk factors or target organ damage, 
such as proteinuria and chronic kidney disease, the tar-
get LDL-C may be further lowered to < 70 mg/dL. 
Patients with diabetes and dyslipidemia need to en-
gage in aggressive lifestyle modification [159]. Individu-
alized education needs to be applied to each patient. For 
patients with diabetes who have poor glycemic control 
and high triglyceride levels, optimizing glycemic con-
trol is helpful for controlling dyslipidemia. Statin is the 
first-line treatment for patients with diabetes and dys-
lipidemia. In a study on patients with diabetes, statin 
therapy significantly contributed to both primary and 
secondary prevention of CVD [160,161]. If the target 
LDL-C goal is not met with the general statin dose, the 
dose should be increased to maximally tolerable dose 
or be substituted by high-intensity statins. Discontinu-
ation of therapy was found to aggravate dyslipidemia in 
type 2 diabetes, so maintenance therapy is crucial, and 
confirming the continuity of medication is also essen-
tial [162].
Whether lowering triglyceride and increasing HDL-C 
with statin/fibric acid derivative therapy are beneficial 
for patients with type 2 diabetes is controversial. The 
ACCORD study found that statin/fibric acid derivative 
therapy did not significantly lower the incidence of 
CVD compared to statin monotherapy. However, in a 
subgroup analysis, the ACCORD study suggested that 
statin/fibric acid derivative therapy may have CVD pre-
ventive effects in patients with triglyceride ≥ 200 mg/dL 
and an HDL-C < 34 mg/dL [50,163].
In the IMPROVE-IT conducted on 18,144 patients 
who were admitted for acute coronary syndrome with-
in 10 days of the study, simvastatin/ezetimibe therapy 
reduced relative risk for CVD by 6.4%. In the subgroup 
analysis, relative risk was reduced by 14% in the diabetes 
group, showing a greater CVD preventive effect among 
patients with diabetes [29]. Adding PCSK9 inhibitors, 
namely evolocumab or alirocumab, to patients with high 
CVD risk who are using maximum statin dose lowered 
LDL-C by 36% to 59% [164,165]. Based on these studies, 
adding ezetimibe or PCSK9 inhibitor may be considered 
for patients with diabetes and CVD if the target LDL-C 
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goal is not met with maximum tolerable dose of statin.
Older adults and dyslipidemia 
South Korea has already become an aged society in 2017, 
as the older adult population (≥ 65 years) reached 14% 
of the total population and it is expected to become a 
super-aged society by 2026, with the older adult popu-
lation estimated to exceed 20% [166]. As a result of the 
growing elderly population, the prevalence and mortali-
ty of CVD are also expected to rise continuously. In par-
ticular, the prevalence of dyslipidemia increases among 
the elderly and many older adults are in the high-risk 
group for CVD; thus, lipid-lowering therapy is expected 
to be highly beneficial. 
The primary preventive effects of statin on older 
adults aged ≥ 70 years have been proven to lower CVD 
and CVD mortality in a study of subjects aged 70 years 
or older and in a subgroup analysis of several large-scale 
studies [116,167,168]. Furthermore, the subgroup analy-
ses on older adults in studies that attempted to examine 
the secondary prevention effects of statin therapy also 
found that statin significantly lowered the incidence of 
CVD without safety problems [169,170]. Therefore, statin 
therapy is recommended for primary and secondary pre-
vention of CVD for older adults. However, evidence sup-
porting the association between cholesterol levels, CVD, 
and mortality as well as the efficacy of statin therapy in 
patients excluded in these clinical trials, such as older 
adults aged ≥ 80 years or frail older adults, is lacking. 
Because elderly patients often have multiple comor-
bidities and reduced organ functions, they are expected 
to have exhibited pharmacological differences in drug 
absorption, distribution, metabolism, and excretion, 
which may increase the risk of adverse drug interaction. 
However, current clinical trials of statin therapy did not 
find a significant increase of adverse reactions, such 
as rhabdomyolysis or increased liver enzyme levels, in 
older adults. Because many elderly patients have mul-
tiple comorbidities or take multiple medications, statin 
should be used while carefully monitoring its interac-
tions with other drugs and its adverse reactions. 
Dyslipidemia in children and adolescents 
For Korean children and adolescents, dyslipidemia is de-
fined as total cholesterol ≥ 200 mg/dL, LDL-C ≥ 130 mg/
dL, non-HDL-C ≥ 145 mg/dL, triglyceride ≥ 130 mg/dL 
(chil dren below age 10, ≥ 100 mg/dL), and HDL-C < 40 
mg/dL according to the 2011 National Heart, Lung, and 
Blood Institute (NHLBI) guideline (Table 13) [171]. How-
ever, according to the fourth National Health and Nu-
trition Examination Survey (2007 to 2010), triglyceride 
levels of 130 mg/dL falls under the 75th to 90th percen-
tile and 150 mg/dL falls under the 90th percentile for 
Korean children and adolescents, which differs from the 
NHLBI’s definition of dyslipidemia. This may be attrib-
utable to the fact that a carbohydrate-based diet is the 
typical staple in South Korea, but additional studies are 
needed to substantiate the criteria for hypertriglyceri-
demia for Korean children and adolescents.
In general, a screening test is not recommended for 
children under the age of 9, and non-HDL-C that does 
not require fasting is recommended for children aged 9 
to 11 years and adolescents aged 17 to 21 years. Children 
not in these age groups are recommended to undergo 
fasting lipid test if they present a risk factor for dyslip-
idemia or have family members with a risk factor (Table 
Table 13. Diagnostic criteria of dyslipidemia for children and adolescents 
Unit, mg/dL Permissible Borderline Abnormal
Total cholesterol < 170 170–199 ≥ 200
LDL-C < 110 110–129 ≥ 130
Non-HDL-C < 120 120–144 ≥ 145
Triglyceride
0–9 yr [171] < 75 75–99 ≥ 100
10–19 yr < 90 90–129 ≥ 130
HDL-C > 45 40–45 < 40
LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.
756 www.kjim.org https://doi.org/10.3904/kjim.2019.188
The Korean Journal of Internal Medicine Vol. 34, No. 4, July 2019
14) [172-175].
Statin therapy should not be immediately initiated 
in children and adolescents even if dyslipidemia is dis-
covered. The decision for drug therapy must be based 
on the mean results of two rounds of fasting lipid test 
performed in 2-week intervals within the past three 
months, and family history and risk factors must be 
assessed. In general, drug therapy is not performed in 
children under the age of 10, and only lifestyle adjust-
ment and dietary therapy (Cardiovascular Health In-
tegrated Lifestyle Diet 1 [CHILD1] → CHILD2-LDL) is 
performed for about six months. However, statin thera-
py may be considered if LDL-C persists to be > 190 mg/
dL [171-176]. Furthermore, drug therapy may be consid-
ered for patients with severe primary hyperlipidemia or 
risk factors for medical complications [177].
Three to 6 months of dietary therapy is applied for 
children and adolescents between the ages of 10 to 21 
years with mean LDL < 250 mg/dL or triglyceride < 500 
mg/dL. Those with a BMI in the 85th percentile should 
be encouraged to reduce calories by increasing physi-
cal activities and altering lifestyle [178]. If the target lip-
id concentration is not met even with these modalities, 
drug therapy may be considered (Fig. 11). If the target 
LDL-C has been met but non-HDL-C is > 145 mg/dL 
in children above the age of 10, statin agents, fibrates, 
or niacin may be considered, and the patients must be 
referred to a specialist [171,179]. If fasting triglyceride is 
between 200 to 499 mg/dL and non-HDL-C is > 145 mg/
dL even after lifestyle adjustment and dietary therapy 
(CHILD1 → CHILD2-triglyceride), the use of omega-3 
fatty acids may be considered [171]. There have been only 
a few cases of pediatric use of omega-3 fatty acid, but no 
safety problems have been reported thus far. Those with 
triglyceride levels > 500 mg/dL must consult a specialist, 
as they have a risk for pancreatitis. 
Familial hypercholesterolemia 
Heterozygous familial hypercholesterolemia
Traditionally, the prevalence of heFH is known to be 
1/500 [180]. Since patients with heFH are exposed to 
high levels of LDL-C over their life-time, they have an 
obviously high-risk of CVD. Accordingly, it is definitely 
important to appropriately diagnose patients as early as 
possible and prevent vascular complications. 
Diagnosis
A patient is likely to have heFH when they present with 
premature CAD at age of < 50 years (male) or < 60 years 
(female) or has family history of FH. Diagnosis can be 
made based on clinical criteria or DNA mutation. Clin-
ical criteria include Simon Broome criteria (Table 15), 
Dutch criteria, and Make Early Diagnosis to Prevent 
Premature Deaths (MEDPED) criteria [181,182]. Cascade 
screening is recommended for family members of a di-
agnosed proband of heFH. 
Treatment
1)  Principles of management of heFH include lifestyle 
modification, lipid-lowering agents, and screening 
for atherosclerotic CVD.
2)  First target of lipid lowering therapy is to reduce 
Table 14. Screening test for dyslipidemia in children and adolescents
Age, yr Recommendation
Birth–2 No screening test necessary
2–8 Screening test not recommended 
Fasting lipid test in presence of family history and risk factora
9–11 Non-HDL-C test without fasting 
If non-HDL-C ≥ 145 mg/dL, fasting lipid testa
12–16 Screening test not recommended
Fasting lipid test when new risk factor or condition is discovered among family membersa
17–21 Non-HDL-C test without fasting 
If non-HDL-C ≥ 145 mg/dL, fasting lipid testa
HDL-C, high density lipoprotein cholesterol.
aTests for fasting lipid profiles should be performed twice at intervals of more than 2 weeks within 3 months.
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LDL-C by 50% of baseline levels. Thereafter, it is de-
sirable to lower LDL-C to < 100 mg/dL (when the 
patient has no CAD or other major risk factors) or to 
< 70 mg/dL (when the patient has CAD or other ma-
jor risk factors). However, the target is not frequent-
ly achieved in real world practice and reduction of 
LDL-C as much as possible with maximal tolerable 
treatment is often a practical objective [183]. 
3)  It is recommended to attempt to achieve the LDL-C 
goal by maximal tolerable dose of statins, the first 
line drug. If the target is not achieved, ezetimibe 
can be added. A considerable proportion of patients 
cannot reach the target and cholesterol binding res-
ins or PCSK9 inhibitors can be added as third line 
agents [6,184]. When patients experience adverse 
events related to statins, second line or third line 
agents can be used instead. 
4)  For children of parents with heFH, DNA testing is 
recommended when a gene mutation in the father 
or mother is identified. Otherwise, it is better that 
they undergo LDL-C measurement. Statin therapy 
can be started at the age of 8–10 years and the target 
is 135 mg/dL at age >10 years [6]. 
Homozygous familial hypercholesterolemia
The prevalence of homozygous familial hypercholester-
olemia (hoFH) is known to be 1/1,000,000 or higher. Be-
cause the exposure of vessels of hoFH patients to lipid is 
more severe than that of heFH patients, the incidence of 
CAD under the age of 20 years is not uncommon.
Diagnosis
One of the most well known international criteria for 
hoFH is that of EAS (2014). It includes DNA mutation, 
LDL-C levels, and family history.
Screening of complications
For examination of CAD or aortic disease, it is desirable 
to consult to cardiologist. Regular screening for compli-
cations is recommended. 
Fasting lipid profile 
Average of two tests
Maintain CHILD-2 LDL-C,
FLP every 6 months
Eliminate secondary causes, investigate risk factors
For 6 months: CHILD-1 → CHILD-2 LDL-C + lifestyle modification
Maintain CHILD-2 LDL-C,
FLP every year
LDL-C ≥ 250mg/dL  →  consult a specialist  TG ≥ 500 mg/dL  →  consult a specialist 
  
TG < 130 mg/dL 
 (for < 10 years: TG < 100)
TG 130–199 mg/dL
(for < 10 years: TG < 100–199)
Maintain CHILD-2 TG, Fasting
 lipid profile every year
CHILD-2 TG, further weight loss
Increase fish intake
Fasting lipid profile after 6 months
Consult a lipid specialist
Consider fibric acid, 
 nicotinic acid including statin
Omega-3 fatty acid
130 ≤ TG < 500 mg/dL (for < 10 years: TG ≤ 100)
For 6 months: CHILD-1 → CHILD-2 TG + weight loss, lifestyle modification
130 ≤ LDL-C < 250 mg/dL
LDL-C < 130 mg/dL
LDL-C 130–189 mg/dL
Family history (–), risk factor (–)
Statin therapy
TG  200–499 mg/dL
→ if LDL-C ≥ 130, TG < 200 mg/dL 
     ppersists, consider secondary drugs
→ even if LDL-C is controlled, if 
     non-HDL-C ≥ 145 mg/dL, TG adjustment
LDL-C 160–189 mg/dL
Family history (+), 1 or more high 
 risk factors or 2 or more moderate 
 risk factors
LDL-C 130–159 mg/dL
2 or more high risk factors or 1 or 
 more high risk factors + 2 or 
 more moderate risk factors or
 clinical CVD
LDL-C ≥ 190 mg/dL
Figure 11. Dyslipidemia treatment algorithm in children and adolescents. LDL-C, low density lipoprotein cholesterol; TG, 
triglyceride; CHILD, Cardiovascular Health Integrated Lifestyle Diet; FLP, fasting lipid profile; CVD, cardiovascular disease; 
HDL-C, high density lipoprotein cholesterol.
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Treatment
The aim of treatment in hoFH is to reduce LDL-C as 
early as possible and as much as possible. Treatment 
targets are 100, 135, and 70 mg/dL in adults, children, 
and patients with atherosclerotic CVD, respectively. 
Lifestyle modification, statins (with ezetimibe), and LDL 
apheresis (if available) are essentials of treatment. LDL 
apheresis is recommended at the age of 5 years or at least 
at age 8 years. New therapeutics such as lomitapide, mi-
pomersen, or PCSK9 can be added.
Cholesterol during pregnancy
Changes in lipid metabolism during pregnancy
Lipids in plasma during pregnancy decrease at the 
first stage and then begin to increase after gestational 
age (GA) of 8 weeks. Increased insulin resistance and 
estrogen stimulation are responsible for the maternal 
hyperlipidemia observed during pregnancy [185]. In the 
first and second trimesters, fat accumulates due to in-
creased food intake and lipogenesis; however, fat accu-
mulation decreases during the third trimester because 
of enhanced lipolytic activity and decreased LPL activity 
[186]. In the later period of pregnancy, insulin resistance 
increases lipolysis, gluconeogenesis, and ketogenesis in 
the fasting state in pregnant women. Insulin increases 
the activity of LPL in adipose tissue and reduces the ac-
tivity of hormone-sensitive lipase, which is a lipolytic 
enzyme. In addition, insulin inhibits hepatic glucone-
ogenesis and ketogenesis. Peripheral insulin resistance 
develops in women with gestational diabetes and plays 
a role in increasing blood nonessential fatty acids and 
ketone body concentration [187]. 
Hyperlipidemia during pregnancy
In the later period of pregnancy, triglycerides, phos-
pholipids, and cholesterol levels increase. In particular, 
the increase of triglycerides is most prominent. Where-
as HDL-C increases after the GA 12 weeks of pregnan-
cy due to the increase of estrogen, the total cholesterol 
and LDL-C increase in the second and third trimesters. 
During pregnancy, hepatic lipase decreases the size of 
triglyceride-rich LDL-C and increases its density. Such 
changes damage endothelial cells and cause atheroma 
formation.
Treatment of dyslipidemia during pregnancy
Lifestyle modifications
Physical activity is effective in preventing gestation-
al diabetes and gestational hypertension. The average 
triglyceride level, of any kind, is lower in women who 
are physically active. For diet therapy, it is difficult to 
make a definitive conclusion and additional studies are 
required.
Omega-3 fatty acid
Omega-3 fatty acids are elements of the diet and are not 
considered to increase adverse effects during pregnan-
cy. There are insufficient data to recommend omega-3 
fatty acid supplements instead of fish intake to normal 
pregnant women. However, supplementation of doco-
sahexaenoic acid is recommended in pregnant women 
who do not usually eat fish at all.
Statins
Statins are contraindicated during pregnancy. Statins 
Table 15. Simon Broome criteria for the diagnosis of heFH
Definite FH If the patient has 
1)  cholesterol level as defineda and tendon xanthoma, or evidence of these signs in first- or second degree 
relative or
2) DNA-based evidence of an LDL-receptor mutation, familial defective apo B-100, or a PCSK9 mutation
Possible FH If the patient has cholesterol level as defineda and at least one of the following
1)  family history of myocardial infarction: aged < 50 years in second-degree relative or aged < 60 years in 
first degree relative.
2)  family history of raised total cholesterol: > 290 mg/dL in adult first- or second degree relative or > 260 
mg/dL in child, brother or sister aged < 16 years.
heFH, heterozygous hypercholesterolemia; FH, familial hypercholesterolemia; DNA, deoxyribonucleic acid; LDL, low density lipo-
protein; apo-B, apolipoprotein B; PCSK9, proprotein convertase subtilisin/kexin type 9.
aTotal cholesterol > 260 mg/dL or LDL-C > 155 mg/dL (child/young person); total cholesterol 290 mg/dL or LDL-C > 190 mg/dL (adult).
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are not thought to increase fetal anomalies during 
pregnancy. Statin therapy is not recommended during 
pregnancy because there is no evidence that dyslipid-
emia treatment is beneficial to pregnant women or that 
cholesterol is required for the growth of embryo during 
pregnancy. A woman who is planning pregnancy or is 
already pregnant, should stop statins, if she is taking 
statins.
FUTURE RESEARCH TOPICS
Cardiovascular biomarkers 
Carotid plaque and intima-media thickness 
In addition to coronary artery calcification, carotid in-
tima-media thickness is one of the most well-known 
surrogate markers of CVD [188]. Adding intima-media 
thickness to the traditional assessment of cardio-cere-
brovascular disease using vascular risk factors enables a 
more detailed classification of risks [66,189]. 
Furthermore, carotid plaques are also considered an 
indicator of asymptomatic atherosclerosis [189]. Coro-
nary plaque is associated with an elevated CVD risk, and 
a plaque of ≥ 4 mm in the aortic arch is a risk factor for 
stroke recurrence [188,190,191]. However, the increase in 
risk associated with coronary plaques is low [188,191].
According to a systematic literature review, statin 
therapy slows the increase of carotid intima-media 
thickness [192]. Furthermore, high-dose statin therapy 
is known to be more effective in treating carotid inti-
ma-media thickness and carotid plaques [193]. However, 
whether targeting the carotid intima-media thickness 
prevents CVD has not been confirmed. Similarly, stud-
ies examining whether carotid plaques can be the target 
of treatment are lacking. In the future, therapeutic effi-
cacy should be investigated in more detail for high-risk 
groups (e.g., echolucent plaques or plaque ulcers).
Vascular calcification
Vascular calcification is commonly observed through-
out the body among older adults. In the past, vascular 
calcification was believed to be a passive change that oc-
curred with aging or harmless changes observed in ath-
erosclerosis. However, recent studies have revealed that 
vascular calcification is associated with hypertension, 
dyslipidemia, diabetes, and renal diseases and that it is 
an actively regulated process similar to bone formation 
[194,195].
Calcification of various systemic arteries, including 
the coronary artery, carotid artery, aorta, and iliac artery, 
is associated, and may be mutually causally related with 
an elevation of systemic blood pressure, pulse pressure, 
and vascular stiffness [195-199]. Further, a systematic 
literature review reported that vascular calcification in-
creases the risk for mortality, CAD, and cerebrovascular 
disease by two to four times [197]. Cerebrovascular calci-
fication is most commonly observed in the intracranial 
internal carotid artery and it has been associated with 
cerebral small vessel diseases, which are a cause of de-
mentia or stroke [200,201].
In particular, coronary arteries have been studied 
more extensively than other blood vessels. Coronary 
artery calcification generally occurs as a result of ath-
erosclerosis and the amount of calcium deposited in 
coronary arteries is believed to be proportional to the 
total amount of atherosclerosis [202-204]. Furthermore, 
multiple studies have reported that coronary artery cal-
cification is associated with vascular disease [203]. In a 
study that investigated the incidence of CVD in four ra-
cial groups, the risk for CAD was about 10 times higher 
in the group with a calcium score of 300 or higher com-
pared to the group without coronary artery calcification 
[205]. In consideration of these findings, existing guide-
lines suggest the use of coronary artery calcification and 
its severity as an indicator for vascular disease risk and 
statin therapy [24,66,206].
However, despite mounting evidence, whether vascu-
lar calcification is an appropriate target of treatment is 
still doubtful. First, evidence supporting that vascular 
calcification is the sole cause of vascular diseases is lack-
ing [188]. Second, although vascular calcification is re-
lated to the overall disease burden from atherosclerosis, 
coronary artery calcification is not directly proportional 
to the degree of stenosis of the coronary artery [204,207]. 
Coronary arteries without calcification may have steno-
sis and severely calcified coronary arteries may not have 
stenosis. Therefore, it is difficult to use coronary artery 
calcification as a surrogate index of vascular stenosis. 
Finally, effective treatment for vascular calcification has 
yet to be identified. 
Subsequent studies should determine the causal re-
lationship between vascular calcification and vascular 
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diseases and develop treatment modalities for vascular 
calcification.
Novel serum markers of atherosclerosis
Atherosclerosis, a major cause of cardio-cerebrovascu-
lar disease, is a chronic inflammatory disease caused by 
injuries of vascular epithelial cells. Foreign treatment 
guidelines present inflammation and thrombus as nov-
el serum markers of atherosclerosis [6,7,24]. However, 
the strength of recommendation is low due to a lack of 
adequate study findings and evidence for novel serum 
markers. Whether serum markers can be used for as-
sessing the risk and treating cardio-cerebrovascular dis-
eases requires further research.
In summary, 
(1)  There is insufficient evidence supporting the use 
of serum markers for atherosclerosis (e.g., hs-CRP, 
fibrinogen, lipoprotein-associated phospholipase 
A2 [Lp-PLA2], homocysteine) in the assessment of 
CVD risk in adults. 
(2)  Serum markers of atherosclerosis (e.g., hs-CRP, fi-
brinogen, Lp-PLA2, homocysteine) may be consid-
ered for assessing potential risk factors in order to 
determine the intensity of treating the risk factors 
for patients at moderate risk of CVD. 
Development and validation of CVD risk assessment tool 
The ACC/AHA cholesterol guideline uses CVD risk as an 
Table 16. Comparison of major cardiovascular disease risk assessment models in the United States [11,33,186-189]
Framingham 
CHD
ATP III
Framingham 
global
Reynolds
Pooled cohort 
equation
Year of publication 1998 2001 2008 2008 2013
Risk factor used
Age X X X X X
Sex X X X X
Total cholesterol X X X X X
LDL-C X
HDL-C X X X X X
CRP X
Systolic BP X X X X X
Use of antihypertensive drugs X X X
Diabetes X X X
HbA1c X (only female)
Smoking X X X X X
Family history X
Target disease
Coronary artery reperfusion X
Angina X
Unstable angina X
Myocardial infarction X X X X X
Coronary artery disease mortality X X X X X
Stroke X X X
Stroke mortality X X X
Heart failure X
CHD, coronary heart disease; ATP, Adult Treatment Panel; LDL-C, low density lipoprotein cholesterol; HDL-C, high density 
lipoprotein cholesterol; CRP, C-reactive protein; BP, blood pressure; HbA1c, glycated hemoglobin.   
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essential factor for determining drug therapy [24]. Table 
16 compares the major CVD risk assessment tools devel-
oped in the United States and the risk factors and scope 
of diseases differ across the models. The ACC/AHA 
guideline adopted the Pooled Cohort Equations devel-
oped by the ACC/AHA Risk Assessment Work Group. 
This tool is characterized by the use of five communi-
ty cohort data to increase the representativeness of the 
data and that the scope of target diseases was expanded 
to include acute MI, stroke, CAD mortality, and stroke 
mortality [208]. 
The 2016 ESC/EAS treatment guidelines mentioned 
the usefulness of CVD risk assessment. Although it rec-
ommends the use of the Systematic Coronary Risk Es-
timation (SCORE) system, it also introduced other risk 
assessment models, including Framingham, ASSIGN 
(CV risk estimation model from the Scottish Intercol-
legiate Guidelines Network), Q-Risk, Prospective Car-
diovascular Munster Study (PROCAM), and the World 
Health Organization (WHO) [6]. The SCORE system was 
developed based on the data from 200,000 individuals 
in 12 cohorts across the European region, and separate 
charts were developed for low-risk countries and high-
risk countries [209].
There have been studies in Korea aiming to develop 
risk assessment models to predict stroke, CAD, and 
overall CVD, and the Globorisk score also provides a 
risk assessment chart for Koreans [13,18,19,210]. Howev-
er, treatment guidelines still do not recommend the use 
of these tools in the decision-making for drug therapy. 
There are concerns that the generalizability of these risk 
assessment tools developed in Korea needs to be fur-
ther examined as they have not been adequately validat-
ed, while others are concerned that even if individual 
CVD risks are assessed, it is difficult to reflect them in 
treatment guidelines because evidence supporting the 
clinical efficacy and cost-effectiveness of drug thera-
py according to the level of risk is lacking. Additional 
studies on CVD risk assessment are needed to develop 
a guideline for the management of dyslipidemia appro-
priate for Koreans. 
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